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bp   base pairs 
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LC   large colony type 
M.   Mycoplasma 
mc   mini circle 
mp   mini plasmid 
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op   original plasmid 
ORF   open reading frame 
pAb   polyclonal antibody 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PLM   phase-locked mutant 
R-H-R-Y  arginine-histidine-arginine-tyrosine 
RNA   ribonucleic acid 
RS   recombination site 
sc   supercoiled 
tRNA   transfer ribonucleic acid 
TBS   tris buffered saline 
U   unit 
UTR   untranslated region 
X-EV   VpmaX expressing escape variant 
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2 Abstract 
2.1 Abstract (English) 
Mycoplasma agalactiae, a cell wall-less bacterium belonging to the class Mollicutes, is considered the 
main etiological agent of the syndrome Contagious Agalactia, which primarily causes mastitis, 
arthritis and conjunctivitis in sheep and goats. Antigenic diversity in M. agalactiae is governed by 
DNA rearrangements within the vpma multigene locus encoding the Vpma family of variable surface 
lipoproteins. Six vpma genes were shown to undergo high-frequency phase variation by site-specific 
DNA inversions mediated by a site-specific recombinase (Xer1) encoded adjacent to the vpma genes. 
Disruption of the xer1 recombinase gene has demonstrated that the Xer1 recombinase is essential for 
site-specific recombination. In the so-called phase-locked xer1 mutants (PLMs) further vpma 
switching by site-specific DNA inversions was abolished and cells were locked in an expression phase 
where only one vpma gene is steadily expressed. In this study, recombination experiments in 
Escherichia coli demonstrated that a putative 21-bp recombination site (RS) located in the 5’ UTR of 
all six vpma genes is indeed involved in Xer1-mediated recombination. Furthermore, adjacent 
nucleotides flanking this conserved 21-bp region were shown to positively influence the 
recombination reaction. The orientation of the RS was crucial for the outcome of the recombination 
reaction. Recombination between inverted repeated RS led to inversions, whereas direct repeated 
alignment of the RS resulted in excisions. Excision events were also successfully demonstrated under 
native conditions in M. agalactiae, using a newly developed assay based on the lacZ reporter gene, 
which was the first application of this reporter system in M. agalactiae.  
Beside site-specific Xer1-mediated recombination, novel molecular mechanisms resulting in Vpma 
surface variation in the absence of the Xer1 recombinase were demonstrated. In another ongoing  
project PLMs lacking the xer1 gene, and therefore steadily expressing only a single Vpma product, 
were used in animal infection studies. Interestingly, PLMs isolated from the animals displayed a new 
Vpma phenotype. Molecular characterization of selected PLM switchover clones revealed that 
complex DNA rearrangements including generation of hybrid vpma genes, as well as gene 
duplications and deletions were triggered in the vpma locus, most likely due to the host immune 
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pressure. Similar Xer1-independent Vpma variation could be demonstrated during in vitro immune 
pressure assays using Vpma-specific antibodies. These results clearly demonstrate that phase variation 
of Vpma surface proteins in M. agalactiae is necessary to survive in the immunocompetent host and 
provide important data for studying similar antigenic variation systems in other pathogenic 
Mycoplasma species. 
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2.2 Abstract (German) 
Mycoplasma agalactiae, ein Vertreter der taxonomischen Klasse Mollicutes, stellt als Erreger der 
Infektiösen Agalaktie der Schafe und Ziegen ein wichtiges pathogenes Bakterium dar. Die klinische 
Symptomatik der Krankheit ist charakterisiert prädominant durch Mastitis, Arthritis und 
Konjunktivitis. Innerhalb des M. agalactiae-Genoms konnte ein einer Pathogenitätsinsel ähnlicher 
Genlokus identifiziert werden, welcher die wichtigsten immunodominanten Oberflächenproteine, die 
sogenannten Vpmas (variable proteins of M. agalactiae) kodiert. Durch ortsspezifische DNA-
Umlagerungen, die durch das Xer1-Protein katalysiert werden, welches in direkter Nachbarschaft zu 
den vpma-Genen kodiert wird, wird die Expression der Vpma-Proteine mit einer ungewöhnlich hohen 
Frequenz variiert. Durch gezielte Disruption des xer1-Gens konnte gezeigt werden, dass die Xer1-
Rekombinase den essentiellen Faktor für ortsspezifische DNA-Inversionen innerhalb des vpma-
Genlokus darstellt. In diesen sogenannten xer1-phase-locked mutants (PLMs) finden daher keine 
spezifischen DNA-Umlagerungen mehr statt, da die Zellen in einer bestimmten Vpma-
Expressionsphase arretiert bleiben. Die vorliegende Arbeit beinhaltet neue Daten bezüglich dieses 
Antigenvariationssystems von M. agalactiae. 
Rekombinationsexperimente in Escherichia coli zeigten, dass vorausgesagte Rekombinationsstellen 
(RS) von 21 bp, welche sich in der 5’ UTR aller sechs vpma-Gene befinden, tatsächlich in Xer1-
katalysierten Rekombinationsereignissen involviert sind. Angrenzende Nukleotide konnten die 
Rekombinationsraten positiv beeinflussen. Zusätzlich konnte gezeigt werden, dass die Anordnung 
dieser RS für das Ergebnis der Rekombinationsereignisse eine essentielle Rolle spielt. Während 
invertiert angeordnete RS zu Inversionen führten, kam es an RS in direkter Abfolge zu 
Exzisionsereignissen. Zusätzlich konnten ortsspezifische Exzisionen im Genom von M. agalactiae 
mithilfe eines neu entwickelten lacZ-Reportersystems  nachgewiesen werden. 
Neben ortsspezifischen DNA-Umlagerungen konnten neue molekulare Mechanismen der Vpma-
Antigenvariabilität von M. agalactiae gezeigt werden, die speziell in der Abwesenheit der Xer1- 
Rekombinase stattfinden. Dazu wurden PLMs, die nur ein bestimmtes Vpma-Genprodukt exprimieren, 
im Tierversuchsmodell verwendet. Überraschenderweise zeigten jene PLMs, die aus den Tieren 
 11
reisoliert wurden, einen neuen Vpma-Phenotyp. Die molekulare Analyse durch DNA-Sequenzierung 
zeigte, dass komplexe DNA-Umlagerungen, wie beispielsweise die Entstehung chimärer vpma-Gene 
bzw. Genduplikation und -deletionen, durch den Selektionsdruck des Immunsystems in den Reisolaten 
stattgefunden haben. Ähnliche Ergebnisse wurden auch in einem neu entwickelten in vitro-Experiment 
unter Selektionsdruck in Gegenwart von Vpma-spezifischen Antikörpern erhalten. Diese neuen Daten 
unterstreichen die Bedeutung der Antigenvariation als wichtige Überlebensstrategie des Erregers M. 
agalactiae in seinem Wirt und repräsentieren eine wichtige Grundlage für die Untersuchung ähnlicher 






3.1 General characterization of the genus Mycoplasma 
The genus Mycoplasma belongs to the taxonomic class Mollicutes representing an important group of 
bacteria that are widespread in nature as commensals and pathogens of plants, animals and humans. 
Mollicutes can be taxonomically distinguished from other bacteria by the total lack of a peptidoglycan 
cell wall. Therefore, they are completely resistant to antibiotics targeting cell wall synthesis such as 
beta-lactams (Baseman and Tully, 1997; Razin et al., 1998).  
Due to their small size and limited genomic capacity, Mycoplasma species are commonly described as 
prototypes of a minimal organism. With remarkably reduced cell sizes ranging from 0.3 µm to 0.8 µm, 
they constitute the smallest autonomously replicating bacteria. Genome sizes vary from 580 kb (M.  
genitalium) (Fraser et al., 1995) to 1,340 kb (M. mycoides subsp. mycoides LC, which is now 
reclassified as M. mycoides subsp. capri) (Manso-Silvan et al., 2009) and are the smallest of all free-
living organisms (Razin, 1997). Additional features of a typical Mycoplasma genome include the 
characteristically low GC-content (25-33 mol %) (Razin et al., 1998) and the use of a typical UGA 
stop codon as a tryptophan codon (Osawa et al., 1992).  
Mollicutes are thought to have evolved from low GC Gram-positive bacteria (Firmicutes) by a so-
called regressive evolution (Woese et al., 1980). Consequently, to favor a small genome, most genes 
for metabolic pathways are missing, which reflects their host-dependent lifestyle. The primary habitats 
of human and animal Mycoplasma species are the mucous surfaces of the respiratory and urogenital 
tracts, the eyes, mammary glands and joints. Infections are usually characterized by clinical symptoms 
like pneumonia, urethritis, conjunctivitis, mastitis and arthritis (Razin et al., 1998). Due to their 
fastidious nutritional requirements they usually exhibit relatively strict host and tissue specificity 
(Rottem and Naot, 1998). Infections with pathogenic Mycoplasma species are usually mild but 
difficult to eradicate and follow a chronic course. For this reason, Mycoplasma species are considered 
very close to the concept of the ‘ideal parasites’ which are properly adapted and rarely kill their hosts 
(Razin et al., 1998; Razin, 1999).  
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Despite their biological attraction as minimal organisms and their medical and economical importance 
as pathogens of human and animals, Mollicutes are also well known contaminants of eukaryotic cell 
line cultures, which cause major problems in research, diagnosis and biotechnological production 
(McGarrity et al.,1992; Rawadi and Dussurget, 1995).  
3.2 Antigenic variation in Mycoplasma species 
The term ‘antigenic variation’ refers to the ability of a microbe to change the antigenic character of its 
cell surface components that are the major targets of the host immune system and consequently allow 
effective avoidance of immune recognition (Razin et al., 1998). In the absence of a cell wall, the 
cytoplasmic membrane is the key element for interaction with the immune system. In order to 
establish chronic infections and to persist in the host, Mycoplasma species are equipped with 
sophisticated molecular systems that promote variation in expression and structure of abundant surface 
lipoproteins (Wise, 1993; Rottem and Naot, 1998). Despite the limited coding capacity of Mycoplasma 
genomes, the number of genes involved in antigenic variation systems is unexpectedly large (Razin et 
al., 1998). Variable surface components can be either encoded by single genes or by multigene 
families (Citti et al., 2005). Several Mycoplasma species have been shown to express surface antigens 
that vary in expression and/or undergo spontaneous changes in size resulting in a remarkably high 
antigenic repertoire on the cell surface (Citti and Rosengarten, 1997; Rosengarten et al., 2000). 
Phase variation is a mode of gene regulation that produces cells within a clonal population that either 
express (phase ON) or do not express (phase OFF) a particular antigen and is usually reversible (van 
der Woude and Baumler, 2004). Several genetic mechanisms associated with phase variation have 
been described in different Mycoplasma species and are governed by minor or major changes in the 
chromosomal DNA of the organism (Citti and Rosengarten, 1997).  
Surface antigens may also undergo spontaneous size variation, which affects their structure, in most 
cases by altering the length of their carboxyl-terminal regions (Citti et al., 2005). Antigen-encoding 
genes frequently include multiple tandem repetitive domains. These modules are hot spots for 
mutations, which expand or contract these repetitive sequences resulting in the expression of different 
size variants of a particular antigenic protein (Razin et al., 1998).  
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The first fully described system of antigenic variation in the genus Mycoplasma was the Vlp system of 
the porcine pathogen M. hyorhinis (Rosengarten and Wise, 1990; 1991). The vlp gene family consists 
of a set of related genes encoding surface lipoproteins, which are switched ON and OFF at high 
frequencies. Regulation of phase variation occurs at the transcriptional level, where spontaneous 
mutations in the poly-(A) sequence of the vlp promoter are responsible for ON and OFF switching of 
the vlp genes. The insertion or deletion of a single adenine nucleotide is sufficient to change the 
expression of a vlp gene (Yogev et al., 1991). Moreover, these membrane proteins may also undergo 
size variation by changing the number of repetitive elements in the C-terminal region, resulting in 
elongated or shortened Vlp molecules (Rosengarten and Wise, 1991). As each phase variation can 
independently be superimposed by size variation, there is a great variety of possible antigenic 
combinations on the surface of M. hyorhinis (Rosengarten and Wise, 1991). 
Variable expression of surface lipoproteins can also occur by a so-called ‘cut and paste’ mechanism 
(Citti et al., 2005). The vsa, vsp and vpma families of M. pulmonis, M. bovis and M. agalactiae, 
respectively, have been documented to use site-specific recombination to alternatively switch between 
ON and OFF expression phase of a particular surface lipoprotein (Ron et al., 2002).  
3.3 Mycoplasma agalactiae 
3.3.1 Current research on M. agalactiae 
During the last decade, a variety of novel tools and information have accumulated to greatly enhance 
the knowledge on the molecular biology and pathogenicity mechanisms of the ruminant pathogen M. 
agalactiae. The discovery of the vpma multigene family (see section 3.3.3.) constitutes an important 
start point for studying molecular pathogenicity of M. agalactiae (Glew et al., 2000). The vpma genes 
have been shown to undergo phase variation by site-specific recombination (see section 3.3.4), which 
resembles a common mechansim of antigenic variation exhibited by many other Mycoplasma species 
(Glew et al., 2002; Ron et al., 2002; Flitman-Tene et al., 2003; Horino et al., 2003). The previous lack 
of tools to genetically manipulate M. agalactiae has so far hampered more refined studies to assess the 
exact function of Vpmas in M. agalactiae infection and disease. However, this has changed since the 
establishment of the first successful transformation protocol, which formed an important step towards 
 15
the genetic manipulation of M. agalactiae (Chopra-Dewasthaly et al., 2005). This was followed by the 
construction of E. coli - M. agalactiae shuttle vectors that were instrumental in the first targeted gene 
disruption via homologous recombination (Chopra-Dewasthaly et al., 2005; 2008). Inactivation of the 
xer1 recombinase gene by homologous recombination (see section 3.3.4) could demonstrate that the 
Xer1 recombinase is indeed the factor involved in vpma gene rearrangements leading to phase 
variation of the corresponding six Vpma surface lipoproteins in the type strain PG2 (Chopra-
Dewasthaly et al., 2008). Also, the construction of specific Vpma phase-locked mutants (PLMs) by 
Xer1 disruption greatly enhanced the ability to evaluate the role of the Vpma lipoproteins during M. 
agalactiae infection studies.  
Furthermore, the genome sequence of the M. agalactiae type strain PG2 is available since 2007 and 
has provided valuable information (Sirand-Pugnet et al., 2007). It constitutes a typical Mycoplasma 
genome with a small size (877 kb), low GC content (29,7%) and high gene compaction. Comparative 
analysis of the M. agalactiae genome with that of other members of the class Mollicutes revealed that 
about 18% genes, several of which encode lipoproteins that are involved in interactions with the host, 
have been horizontally transferred from Mycoplasma species of the mycoides cluster that are 
phylogenetically different but share with M. agalactiae common ruminant hosts (Sirand-Pugnet et al., 
2007). This large scale acquisition of foreign genes represents an important evolutionary aspect that 
stands in contrast with the generally accepted scenario that gene loss is the main driving force of 
Mycoplasma evolution (Sirand-Pugnet et al., 2007).  
In a recent genomic study, an extended repertoire of vpma genes was shown to be distributed over two 
distinct loci in the M. agalactiae field strain 5632 as compared to the single vpma locus found in the 
type strain PG2 (Nouvel et al., 2009).   
3.3.2 The Contagious Agalactia syndrome 
M. agalactiae is the main etiological agent of the syndrome Contagious Agalactiae (CA) of sheep and 
goats and represents one of the most important diseases in small ruminants caused by Mycoplasma 
species (Bergonier et al., 1997). The pathogen was isolated by Bride and Donatien in 1923 as the 
second known Mycoplasma species (Madanat et al., 2001). The disease was first described by Metaxa 
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(Italy) in 1816 and was given the name CA by Brusasci in 1871 (Bergonier et al., 1997; Madanat et 
al., 2001). CA is mainly characterized by the clinical symptoms of mastitis in lactating females. Males, 
young animals and non-lactating females suffer from arthritis, conjunctivitis and respiratory problems 
(Bergonier et al., 1997; Madanat et al., 2001; Corrales et al., 2007). Although M. agalactiae is 
considered the ‘classical’ agent of CA, yet M. capricolum subsp. capricolum, M. putrefaciens, M. 
mycoides subsp. mycoides LC, which is now reclassified as M. mycoides subsp. capri, can also 
produce a clinically similar disease (Bergonier et al., 1997; Manson-Silvan et al., 2009).  
At present, CA is notifiable to the World Organization for Animal Health and occurs mainly in the 
Mediterranean area, but also on the Balkan peninsula, in western Asia and in northern, central and 
eastern Africa, leading to considerable economic losses mainly due to reduction in milk yields, but 
also due to pneumonia, abortion and in rare cases mortality (Nicholas, 2002; Corrales et al., 2007).  
Under natural conditions, M. agalactiae transmission occurs through direct contact between infected 
and healthy animals. Young animals are commonly infected while suckling contaminated colostrum or 
milk. Also, infection can occur via contaminated milking equipment or the hands of the milker  
(Madanat et al., 2001). 
The clinical diagnosis of CA is based on the presence of typical clinical signs related to the disease, 
which are rarely characteristic, so isolation and identification of the infectious agent is essential to 
confirm disease outbreaks (Nicholas, 2002). The most suitable samples for diagnosis are milk, mastitic 
secretion, joint fluid or eye swabs (Madanat et al., 2001; Nicholas, 2002) which are used for 
cultivation in liquid or on solid media (Lambert, 1987). Also, many serological tests have been 
developed to detect CA, which are especially useful for epidemiological studies, but all share 
difficulties related to cross-reactivity between closely related species (Corrales et al., 2007). These 
difficulties can be overcome by the use of molecular techniques and monoclonal antibodies  
(Bergonier et al., 1997; Corrales et al., 2007). 
Controlling the disease by antibiotic therapy is usually ineffective, because such therapy reduces the 
clinical symptoms but fails to eliminate the causative agent and therefore promotes the carrier state 
(Nicholas, 2002). Prevention of CA caused by M. agalactiae by vaccination is widely used in the 
Mediterranean countries of Europe and the Middle East. Live vaccines have been used for many years 
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in Turkey and have been reported to provide better protection in ewes and their lambs than inactivated 
vaccines, but may produce a transient infection with shedding of the pathogen. In Europe, where live 
vaccines for M. agalactiae are not acceptable, attention has focused on the use of inactivated 
organisms. Globally, no single vaccine has been adopted and no standard method of evaluation and 
preparation has been applied (Nicholas et al., 2009).  
3.3.3 The vpma multigene locus 
Within the genome of the M. agalactiae type strain PG2 a multigene locus was identified that contains 
six distinct but related genes that encode the major antigenic surface lipoproteins, the Vpmas (variable 
proteins of M. agalactiae) (Glew et al., 2000; 2002; Flitman-Tene et al., 2003). DNA sequencing and 
protein analysis revealed that all vpma genes (vpmaU to vpmaZ) share a highly conserved 5’ 
untranslated region (UTR), and a common leader sequence which ends in protease cleaving site. Based 
on their N-terminal sequence, vpma genes can be divided into two homology groups. Group one 
includes vpmaW, vpmaX and vpmaY and is characterized by a short region of high identity after the 
leader sequence, whereas group two consists of vpmaV, vpmaU and vpmaZ sharing common regions. 
Additionally, repetitive domains were identified within vpma genes, which are either fully or partially 
repeated within one gene, but may also form a part of a different vpma gene. A unique promoter is 
also present in the locus, which enables the expression of the downstream vpma gene (Glew et al., 
2002). 
However, two ORFs (ORF2’ and xer1) unrelated to the vpma genes were identified at one end of the 
vpma locus of PG2. Whereas the function of ORF2’ is unknown, the other ORF, designated as xer1, 
was shown to have significant homology to genes belonging to the λ-integrase family of site-specific 
recombinases which are characterized by an invariant tetrad of the amino acids R-H-R-Y that are 
involved in catalysis (Glew et al., 2002). It was shown that the Xer1 recombinase is responsible for 
phase variation of the vpma genes (Chopra-Dewasthaly et al., 2008). A tRNA gene was found between 
the two ORFs and appears to be unrelated to genes from Mycoplasma species and may constitute a 
hotspot for integration of foreign DNA (Glew et al., 2002). The presence of possible virulence genes 
(vpma mulitgene family), a ‘mobility gene’ (xer1) and a tRNA gene (tRNA-lys) suggests that the 
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vpma locus is a ‘pathogenicity island-like’ locus that constitutes a region of a chromosome encoding 
putative pathogenicity related genes (Hacker et al., 1997; Glew et al., 2002). 
3.3.4 Molecular mechanism of Vpma antigenic variation in M. agalactiae 
It has been demonstrated that the vpma genes undergo phase variation at high frequencies in vitro (10-2 
to 10-3 per cell per generation) in the M. agalactiae type strain PG2 (Glew et al., 2000; Chopra-
Dewasthaly et al., 2008). Only one vpma gene is transcribed at a given time from a single promoter 
present in the vpma locus, while all other vpma genes remain silent (Glew et al., 2002). The Xer1 
recombinase encoded adjacent to the vpma genes was predicted to mediate DNA inversions 
responsible for switching the promoter from an active vpma gene to a silent one resulting in alteration 
of vpma expression. Sequence alignment of the vpma genes identified a conserved 21-bp region within 
the 5’ UTR of all vpma genes that was thought to constitute the recombination site (RS) involved in 
Xer1-mediated inversions (Glew et al., 2000; Flitman-Tene et al., 2003). Disruption of the xer1 gene 
in PG2 by homologous recombination proved that the Xer1 recombinase is indeed responsible for 
Vpma phase variation in M. agalactiae (Chopra-Dewasthaly et al., 2008). In the xer1 knock-out 
mutants of PG2, further Vpma switching is abolished, and expression is blocked in a phase where only 
one vpma gene is steadily expressed. Complementation of the wild-type xer1 gene in these phase-
locked mutants (PLMs) restored Vpma phase variation (Chopra-Dewasthaly et al., 2008).  
The vsa family of the murine pathogen M. pulmonis and the vsp family of the bovine pathogen M. 
bovis, the two phylogenetically close relatives of M. agalactiae, use very similar molecular 
mechanisms for generating surface diversity by DNA rearrangements (Ron et al., 2002). In both 
systems, as in the vpma locus, ON and OFF switching is mediated by a site-specific recombinase of 
the λ-integrase family and both contain a single promoter that drives the expression of only one gene 
within the multigene locus. However, the HvsR site-specific recombinase of M. pulmonis is known to 
exhibit a dual substrate specificity mediating ON and OFF switching of vsa genes, and also causing 
DNA inversions in the hsd locus resulting in the phase variable production of restriction enzymes with 
different sequence specificity (Sitaraman et al., 2002).  
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DNA rearrangements also govern phase variation of the Mpl lipoproteins that are encoded by the mpl 
gene family found as three different gene clusters in the human pathogen M. penetrans (Neyrolles et 
al., 1999; Röske et al., 2001; Sasaki et al., 2002). However, this molecular switch differs from the vsa 
and vsp families of M. pulmonis and M. bovis respectively, as each mpl gene has its own invertible 
promoter and can be individually switched ON and OFF, resulting in a large number of possible Mpl 
surface configurations (Horino et al., 2003). 
Recent studies on the M. agalactiae field strain 5632 revealed a much higher repertoire of vpma genes 
compared to the type strain PG2 (Nouvel et al., 2009). A total of 23 vpma genes are distributed in two 
distinct loci, both containing a xer1 recombinase gene and a single promoter allowing concomitant 
Vpma switching and expression in these loci. Several of these newly described vpma genes in strain 
5632 display chimeric structures that are thought to be generated by homologous recombination events 
between different vpma genes, gene duplication, and/or insertion-deletion of repeated motives (Nouvel 
et al., 2009). 
3.4 Site-specific recombination 
3.4.1 General characteristics of site-specific recombination 
DNA rearrangements in bacteria may either occur by general recombination between homologous 
DNA sequences or by a variety of specialized recombination events, such as site-specific 
recombination that is focused at specific sites in the genome. In a typical site-specific recombination 
reaction, a recombinase enzyme acts at well defined RS that are necessary for recombination and that 
contain the point of strand exchange. Site-specific recombination systems are widespread among 
bacteria and, depending on the orientation of the participating RS, serve various biological functions 
(see section 3.4.3) (Nash, 1996; Hallet and Sherratt, 1997). Important features of site-specific 
recombination are that (i) the recombination reaction may occur in the absence of replication, (ii) 
energy co-factors (such as ATP) are not required, (iii) and strand exchange is completed without any 
DNA synthesis or degradation. Depending on the catalytic mechanism used during recombination, 
site-specific recombinases can be separated into two distinct groups, which are referred to as the the λ-
integrase family and the resolvase/invertase family (Nash, 1996; Hallet and Sherratt, 1997). 
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3.4.2 The λ-integrase family of site-specific recombinases 
Members of the λ-integrase family of site-specific recombinases are characterized by four strongly 
conserved amino acid residues (R-H-R-Y) within the C-terminal half of the protein. Except for the    
R-H-R-Y tetrad, members of the λ-integrase family show only little sequence similarity with one 
another (Nunes-Düby et al.,1998). The recombination reaction proceeds via sequential strand 
exchange by formation and resolution of a Holliday structure intermediate during which the 
recombinase is covalently linked to the DNA by the tryosine residue (Hallet and Sherratt, 1997). This 
feature distinguishes the λ-integrase family from members of the resolvase/invertase family, which use 
a different mechanism for recombination (Hallet and Sherratt, 1997; Smith and Thorpe, 2002). Well 
studied members of this family include the lamdba Int protein, the Cre protein of the phage P1 and the 
XerC and XerD recombinases of E. coli amongst many others.  
3.4.3 Recombination sites (RS) involved in site-specific recombination 
RS constitute DNA sequences where recombinase binding and strand exchange takes place. The 
disposition of the involved RS in a site-specific recombination reaction plays a crucial role for its 
outcome and biological function. Intramolecular recombination between direct repeated RS usually 
results in excision of the interjacent DNA fragment, whereas recombination between inverted repeated 
RS inverts the fragment flanked by the two RS. Recombination between two RS present on separated 
DNA molecules leads to integration of one molecule into the other (Hallet and Sherratt, 1997).  
Excision events usually resolve multimers of circular replicons (e.g. bacterial chromosomes, plasmids, 
circular phage genomes), which may arise through homologous recombination events after replication 
and therefore play an important role during segregation of genetic material to daughter cells. Also 
excision and integration allow switching between the lytic and lysogenic life cycles of temperate 
bacteriophages (Barksdale and Arden, 1974; Landy, 1989). In contrast, site-specific inversions are 
usually associated with the generation of genetic diversity by controlling the expression of phase 
variable proteins (e.g. expression of surface antigens, flagella proteins, tail fibers of bacteriophages) 
(Nash, 1996). 
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Typically, RS of the λ-integrase family contain a central part of 6-8 bp that is referred to as the overlap 
region within which strand cutting and exchange occurs. The overlap region is flanked by two inverted 
repeated sequences that act as recombinase binding elements. Besides the overlap region and the 
recombinase binding elements, both of which constitute the functional core of the RS, many site-
specific recombination systems require additional factors (e.g. extra DNA binding sites for accessory 
proteins, precise DNA structure) that control the outcome of the reaction (Nash, 1996; Hallet and 
Sherratt, 1997). 
3.4.4 Mycoplasma site-specific recombinases 
Analysis of the amino acid sequences of Mycoplasma proteins (Xer1 of M. agalactiae, Mbr of M. 
bovis and HvsR of M. pulmonis) that are associated with phase variation by site-specific DNA 
rearrangements revealed that these proteins are members of the λ-integrase family (Ron et al., 2002). 
The C-terminal regions of these proteins carry the R-H-R-Y tetrad that is involved in catalysis. The C-
terminal part of Mycoplasma recombinases was also shown to exhibit significant sequence similarities 
with the XerC and XerD recombinases of E. coli (Ron et al., 2002) that resolve multimeric forms of 
circular replicons to allow efficient segregation of monomers to daughter cells at cell division (Blakely 
et al., 1991; Blakely et al., 1993). 
3.5 Work description 
The work presented in this thesis focuses on the dynamics of Vpma surface variation in the ruminant 
pathogen M. agalactiae. The publication ‘Xer1 Mediated Site-specific DNA-Inversions and 
Excisions in Mycoplamsa agalactiae’ describes recombination experiments carried out in E. coli, 
which clearly demonstrate that the Xer1 recombinase catalyzes vpma gene inversions at conserved 
vpma RS located in the 5’ UTR of all six vpma genes. The orientation of the RS was shown to be 
crucial for the outcome of the recombination reaction. Recombination between inverted repeated RS 
led to inversions, whereas direct repeated alignment of the RS resulted in excisions. Furthermore, 
Xer1-mediated excision events were also successfully demonstrated in M. agalactiae, using a newly 
developed lacZ gene-based assay, which is the first application of this reporter system in M. 
agalactiae. 
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Another ongoing project deals with the evaluation of the biological significance of Vpma proteins and 
their phase variation in pathogenesis. To adress this question, animal infection trials were performed 
using xer1-deficient PLMs that were previously demonstrated to steadily express a single Vpma 
product for many generations during in vitro growth (Chopra-Dewasthaly et al., 2008). Interestingly, 
PLMs isolated from the animals displayed new Vpma phenotypes. The collection of data ‘Xer1-
independent Mechanisms of Vpma Phase Variation are Triggered by the Presence of Vpma-
specific Antibodies’ deals with the molecular characterization of novel escape mechanims that 
resulted in Vpma switching in these PLM clones in the absence of the Xer1 recombinase. Complex 
DNA rearrangements including generation of hybrid vpma genes, as well as gene duplications and 
deletions were triggered most likely by the host immune response. Similar mechanisms could be 
demonstrated in vitro under the immune pressure of the Vpma-specific antibodies. These results cleary 
demonstrate the requirement of Vpma surface alteration as a survival strategy in the native host and 
provide important data for studying similar antigenic variation systems in other Mycoplasma species. 
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Abstract  
Surface antigen variation in Mycoplasma agalactiae, the etiological agent of Contagious Agalactia in 
sheep and goats, is governed by site-specific recombination within the vpma multigene locus encoding 
the Vpma family of variable surface lipoproteins. This high-frequency Vpma phase switching was 
previously shown to be mediated by a Xer1 recombinase encoded adjacent to the vpma locus. In this 
study it was demonstrated in E. coli that the Xer1 recombinase is responsible for catalyzing vpma gene 
inversions between recombination sites (RS) located in the 5’ untranslated region (UTR) of all six 
vpma genes causing cleavage and strand exchange within a 21 bp conserved region that serves as a 
recognition sequence. It was further shown that the outcome of the site-specific recombination event 
depends on the orientation of the two vpma RS as direct or inverted repeats. While recombination 
between inverted vpma RS led to inversions, recombination between direct repeated vpma RS led to 
excisions. Using a newly developed excision assay based on the lacZ reporter system, we were able to 
successfully demonstrate under native conditions that such Xer1-mediated excisions can indeed also 
occur in M. agalactiae type strain PG2, whereas they were not observed in the control xer1-disrupted 
VpmaY phase-locked mutant (PLMY) which lacks Xer1 recombinase. Unless there are specific 
regulatory mechanisms preventing such excisions, this might be the cost that the pathogen has to 
render at a population level for maintaining this high-frequency phase variation machinery.  
 
INTRODUCTION 
Members of the bacterial class Mollicutes, which are generally referred to as mycoplasmas are 
considered one of the simplest self-replicating prokaryotes carrying minimal genomes. Even though 
having lost many biosynthetic pathways during a reductive evolution, mycoplasmas represent 
important pathogens of humans, animals and plants, as they are equipped with sophisticated molecular 
mechanisms allowing them to spontaneously change their cell-surface repertoire to persist in immune-
competent hosts (25).  
The important ruminant pathogen Mycoplasma agalactiae causes Contagious Agalactia in sheep and 
goats and exhibits antigenic diversity by site-specific DNA rearrangements within a pathogenicity 
island-like gene locus (9, 10, 26). The so-called vpma locus constitutes a family of six distinct but 
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related genes that encode major immunodominant membrane lipoproteins, the Vpmas (variable 
proteins of Mycoplasma agalactiae) (10, 11). These surface-associated proteins vary in expression at 
an unusually high frequency, and only one vpma gene is transcribed at a time from a single promoter 
present in that locus, while all other genes are silent (9, 10). An ORF having homology to the λ-
integrase family of site-specific recombinases was found in the vicinity of the vpma locus and was 
predicted to mediate DNA inversions responsible for switching the promoter from an active vpma 
gene to a silent one, resulting in alteration of vpma expression (9, 10). This recombinase, designated as 
Xer1, was recently demonstrated to be indeed responsible for phase variation of Vpma proteins (4). 
Targeted knockouts of the xer1 gene by homologous recombination prevented Vpma switching and 
produced Vpma phase-locked mutants (PLMs) steadily expressing a single vpma gene without any 
variation. Complementation of the wild-type xer1 gene in these PLMs restored Vpma phase variation 
(4). Similar systems generating surface diversity by DNA inversions involving site-specific 
recombination have been identified in other mycoplasma species (3, 18, 26). 
Site-specific recombination systems are widespread among bacteria, and the biological functions of 
these systems strongly depend on the participating recombination sites (RS) (16, 24, 27). Excision 
events between direct repeated RS usually resolve chromosome- or plasmid-dimers, which can arise 
through homologous recombination, ensuring proper segregation of newly replicated genetic material 
to daughter cells (1). Also, site-specific recombination mediates integration and excision of phage 
genomes into and out of the host chromosome (13). In contrast, site-specific inversion involving 
inverted repeated RS generates genetic diversity and often controls the expression of genes that are 
important for pathogenesis (21). 
The Xer1 recombinase of M. agalactiae belongs to the λ-integrase family of site-specific 
recombinases (10). Members of this family share four strongly conserved amino acid residues (R-H-R-
Y) within the C-terminal half of the protein. This tetrad includes the active tyrosine residue that is 
directly involved in the recombination reaction (8). Recombination occurs by formation and resolution 
of a Holliday junction intermediate involving a covalent linkage between the recombinase and the 
DNA through the tyrosine residue. Since energy co-factors such as ATP are not required, such 
recombination events can occur in the absence of replication (16, 24). 
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Sequence alignment of vpma genes identified a conserved 21-bp region within the 5’ untranslated 
region (UTR) of all vpma genes that was predicted to be involved in Xer1-mediated inversions (10). 
The present study clearly demonstrates that the Xer1 recombinase recognizes RS located within the 5’ 
UTR of vpma genes causing cleavage and strand exchange within a conserved region of 21 bp. By 
placing two vpma-derived RS on a plasmid along with the xer1 gene, recombination events were 
demonstrated in E. coli upon Xer1 induction via PCR and restriction analysis. Although the conserved 
21-bp region was sufficient for inversions, additional nucleotides flanking it at the 5’ end were found 
to have a positive influence on the rate of recombination. An interesting outcome of these studies was 
that Xer1 also mediates excisions between direct repeated vpma-RS in E.coli. This raised the 
intriguing possibility that such Xer1-mediated excisions also occur in the native M. agalactiae system. 
For further analysis of such excision events in the native system, we tested the feasibility of using the 
lacZ reporter tool in M. agalactiae, as lacZ is known to be successfully expressed in few other 
mycoplasma species to study gene expression by promoter probe vectors (15, 19, 22, 23). We 
developed an excision assay based on blue/white phenotype selection to study Xer1-mediated 
excisions in M. agalactiae, thus displaying a novel application of the lacZ reporter gene in 
mycoplasmas. Successful implementation of this reporter system demonstrated Xer1-mediated 
excisions in the M. agalactiae type strain PG2 based on blue/white selection and PCR analysis. As 
expected, such excisions were not observed in the control xer1-disrupted VpmaY phase-locked mutant 
(PLMY) which lacks Xer1. Excisions in the native system imply that genetic material is susceptible to 
loss, which might be the cost for maintaining the machinery of high-frequency gene shuffling for a 
greater population advantage, unless there are specific regulatory mechanisms preventing such 
excisions. 
MATERIALS AND METHODS 
Bacterial strains, plasmids and growth conditions. E. coli strain DH10B (Invitrogen GmbH, Lofer, 
Austria) was used for cloning and expression of the xer1 gene. Plasmids used for Xer1-mediated 
excision and inversion experiments in E. coli were derived from pBAD24 (14), and plasmid constructs 
for studying excisions in M. agalactiae were derived from pISM2062 (22). Plasmids p5H1.8 (11), 
p5H4.7 (10) and pAWC10-lac (20) have been described elsewhere. Excision studies were carried out 
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within M. agalactiae type strain PG2 (32) and the xer1-disruptant strain PLMY (4). Cells were grown 
in SP4 (33) broth and transformants were selected on SP4 agar plates containing gentamicin (50 
µg/ml) and/or tetracycline (2 µg/ml) as appropriate. To monitor lacZ expression on the basis of 
blue/white selection, M. agalactiae cells carrying the lacZ gene were grown on SP4 agar plates 
supplemented with 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) at a concentration of 
160 µg/ml. 
 
DNA manipulations. Preparation of plasmid and genomic DNA and isolation of DNA fragments 
from agarose gels were carried out using suitable kits from Promega (Promega Wizard SV Gel and 
PCR Clean-Up System, Promega, Mannheim, Germany), PEQLAB (EZNA Plasmid Miniprep Kit I, 
PEQLAB-Biotechnologie GmbH, Erlangen, Germany) and QIAGEN (QIAamp DNA Mini Kit, 
QIAGEN GmbH, Hilden, Germany). Restriction endonucleases and nucleotides were purchased from 
Promega, T4 DNA Ligase from Roche (Roche Diagnostics, Vienna, Austria) and Antarctic 
Phosphatase from New England Biolabs (New England Biolabs, Frankfurt am Main, Germany). 
Transformation of E. coli cells was performed by electroporation with a BIO-RAD Gene-PulserRII 
(Bio-Rad Laboratories GmbH, Vienna, Austria) using 1.25 V voltage, 25 μF capacitance and 200 Ω 
resistance. Transformation of M. agalactiae cells was carried out as described (5). Oligonucleotide 
synthesis and sequencing were carried out at VBC-Biotech Service (VBC-Biotech Service GmbH, 
Vienna, Austria). Standard molecular procedures were performed as described by Sambrook et al (28). 
  
xer1 induction experiments in E. coli. E. coli DH10B transformed with plasmids used for inversion 
and excision experiments were plated on LB agar plates containing ampicillin (100 µg/ml) and 5% 
glucose for inhibition of basal expression from the PBAD promoter and grown overnight at 28°C. 
Individual transformants were picked, inoculated in LB broth containing ampicillin and glucose and 
grown overnight at 28°C. For xer1 induction, 600 µl of the overnight culture was transferred into 60 
ml LB broth containing 100 µg/ml ampicillin and cells were grown at 37°C. Growth of bacteria was 
monitored by measurement of the optical density at 600 nm (OD600). At an OD600 of 0.3, xer1 
expression was induced by adding 0.5% L-arabinose. Samples for plasmid preparations were removed 
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at different time points (2 h, 4 h, 6 h and 20 h) as appropriate. Samples for plasmid preparation of 
uninduced cultures serving as negative controls were taken from overnight cultures and/or at the 
beginning of induction. Plasmid samples were used for subsequent PCR- and restriction analysis 
assays. 
 
PCR amplification. PCR reactions for cloning (except amplification of the lacZ gene) were carried 
out in a total volume of 100 µl consisting of 50 ng template DNA, 1 µM of each primer, 25 mM 
MgCl2, 0.2 µM dNTPs and 5 U of Taq DNA polymerase (Promega) in 1 x PCR buffer supplied by the 
manufacturer. Cycling parameters consisted of 1 cycle of 3 min at 94°C for initial denaturation 
followed by 30 cycles of 1 min denaturation at 94°C, 1 min at various annealing temperatures (60°C 
for xer1, 58-63°C for the 200-bp vpmaY-RS, 57°C for RS111Y and 58°C for RS184U) and 1 min at 
72°C for extension, and a final extension step of 5 min at 72°C. 
The lacZ gene with its native Shine-Dalgarno sequence from E. coli was amplified in a 100 µl mix 
constituting 50 ng of plasmid pAWC10-lac, 1 µM of primers LacfwBN (containing BamHI and NcoI 
sites for subsequent clonig) and LacrvSB (containing SmaI and BglII sites), 0.2 µM dNTPs, 1 U of 
Long PCR Enzyme mix (Fermentas GmbH, St. Leon-Rot, Germany) and 1 x PCR buffer (containing 
25mM MgCl2) supplied by the manufacturer. Cycling conditions consisted of 1 cycle of 2 min at 94°C 
for initial denaturation, 10 cycles of 20 s at 94°C for denaturation and 3 min at 68°C for extension, 
followed by 20 cycles of 20 s at 94°C for denaturation and 3 min 20 s at 68°C for extension and a final 
extension step of 10 min at 68°C. 
A three primer hot-start PCR for detection of inversion events was accomplished in a 25 µl volume 
containing 25 ng of template DNA, 1 µM of primers P1 and P2, 0.2 µM of primer P4, 2.5 mM MgCl2, 
0.2 µM dNTPs, 1 M betaine and 5 U of HOT FIREPol DNA polymerase I (Solis BioDyne OU, Tartu, 
Estonia) in 1 x PCR buffer supplied by the manufacturer. Cycling parameters consisted of 1 cycle of 
15 min at 95°C for initial denaturation, followed by 30 cycles of 43 s denaturation at 94°C, 43 s 
annealing at 61°C and 1 min 33 s at 72°C for extension and a final extension step of 10 min at 72°C. 
PCR for the detection of Xer1-mediated excision events in M. agalactiae was carried out in a volume 
of 25µl, which consisted of 10 ng genomic DNA obtained from PG2 or PLMY transformants, 1 µM of 
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primers 184Ubfw and ISR-f, 2.5 mM MgCl2, 0.2 µM dNTPs and 5 U of HOT FIREPol DNA 
polymerase I (Solis BioDyne OU, Tartu, Estonia) in 1 x PCR buffer supplied by the manufacturer. 
Cycling parameters consisted of 1 cycle of 15 min at 95°C for initial denaturation, followed by 30 
cycles of 1 min denaturation at 94°C, 1 min annealing at 55°C and 3 min 50 s extension at 72°C and a 
final extension step of 5 min at 72°C. 
 
Plasmid constructions. Construction of plasmids pBADRS21x2 and pBADXerRS21x2. 2 µg of each 
of the primers Ol1new2sen and Ol1new2asen (oligonucleotides are summarized in Table 1) were 
mixed with 46 µl of annealing buffer (100 mM potassium acetate, 30 mM HEPES, 2 mM magnesium 
acetate, pH 7.4), boiled at 100°C for 5 min and cooled down gradually to room temperature within 60 
min. The resulting double-stranded 21-bp RS contained HindIII and XbaI overhangs and was ligated 
into HindIII and XbaI sites of pBAD24. The ligation mixture was transformed into E. coli DH10B by 
electroporation as described resulting in plasmid pBADRS21. Another 21-bp RS was introduced into 
the NsiI and NarI sites of pBADRS21 to obtain a vector with two inverted repeated 21-bp RS. The 
second 21-bp RS containing NsiI and NarI overhangs was similarly obtained by annealing 
oligonucleotides RS21NsiI and RS21NarI and ligated into the corresponding sites of pBADRS21 to 
obtain vector pBADRS21x2 containing two inverted repeats of the 21-bp RS. The xer1 gene was 
amplified from plasmid p5H4.7 using primers RecATGET28 (containing NcoI site) and XerrvSma 
(containing SmaI site). The 750-bp product was digested with NcoI and SmaI and cloned at the 
corresponding sites of pBADRS21x2 resulting in plasmid pBADXerRS21x2. 
Construction of plasmids pBADXerIR200Y and pBADXerDR200Y. A 200-bp fragment containing the 
vpmaY-RS corresponding to the 5’ UTR of vpmaY gene was obtained by PCR amplification as 
described using plasmid p5H1.8 as template and oligonucleotides RSmcsX (containing a XbaI site) 
and RSmcsH (containing HindIII site) as primers. The HindIII- and XbaI-digested amplicon was then 
ligated into the corresponding sites of pBAD24 resulting in plasmid pBADRS. Another copy of the 
200-bp fragment was introduced into plasmid pBADRS both as a direct and as an inverted repeat after 
PCR amplification from plasmid p5H1.8 using oligonucleotide pair Rsd1cla (containing a ClaI site) 
and Rsd1nsi (containing a NsiI site) for direct repeated RS, and oligonucleotide pair Rsd2cla 
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(containing a ClaI site) and Rsd2nsi (containing a NsiI site) for inverted repeated RS. The 200-bp PCR 
fragments were cut with ClaI and NsiI and introduced into NsiI and NarI cut plasmid pBADRS. NarI 
and ClaI produce compatible cohesive ends and therefore NarI overhangs can be ligated to ClaI 
overhangs. The two plasmids were designated pBADDR (direct repeated RS) and pBADIR (inverted 
repeated RS). The xer1 gene was introduced into plasmids pBADDR and pBADIR as described for 
plasmid pBADXerRS21x2 resulting in plasmids carrying two 200-bp RS either as inverted 
(pBADXerIR200Y) or as direct repeats (pBADXerDR200Y) along with the xer1 gene. 
Construction of plasmids pBADXerIR21Y, pBADXerIR31Y3’, pBADXerIR56Y3’, pBADXerIR57Y5’ 
and pBADXerIR111Y. Oligonucleotides Ol1new2sen and Ol1new2asen were annealed to obtain 
RS21Y, Oligo#2sense and Oligo#2asense for RS31Y3’, Oligo#3sense and Oligo#3asense for 
RS56Y3’ and Ol9sen and Ol9asen for RS57Y5’. The annealed oligonucleotides carried XbaI and 
HindIII overhangs for cloning into the corresponding sites of pBADXerIR200Y resulting in plasmids 
pBADXerIR21Y, pBADXerIR31Y3’, pBADXerIR56Y3’ and pBADXerIR57Y5’, respectively. 
RS111Y was obtained by PCR as described using plasmid p5H1.8 as template and oligonucleotides 
pBADoligo#4fw (containing a XbaI site) and pBADoligo#4rv (containing a HindIII site) as primers. 
The HindIII- and XbaI-cut PCR product was introduced into the corresponding sites of 
pBADXerIR200Y resulting in plasmid pBADXerIR111Y. 
Construction of plasmids pBADXer200Y/184U, pBADXerIR200Y/56X5’ and pBADXer53U5’/57Y5’. 
Plasmid pBADXer200Y/184U was obtained by replacing the XbaI- and HindIII-cloned 200-bp vpmaY 
RS of pBADXerIR200Y with a 184-bp vpmaU-RS generated by PCR using plasmid p5H4.7 as 
template and PrimerRSU (containing a XbaI site) and RSmcsH (containing a HindIII site) as primers. 
The PCR fragment restricted with HindIII and XbaI was cloned into the corresponding sites of vector 
pBADXerIR200Y resulting in plasmid pBADXerIR200Y/184U containing a 200-bp vpmaY-RS and a 
184-bp vpmaU-RS aligned as inverted repeats. Similarly plasmid pBADXerIR200Y/56X5’ was 
obtained by replacing the XbaI- and HindIII-cloned 200-bp vpmaY RS with a 56-bp RS originating 
from the vpmaX gene. Oligonucleotides OligoRSXsen and OligoRSXasen were annealed as described. 
The obtained fragment containing XbaI and HindIII overhangs was cloned into the corresponding sites 
of vector pBADXerIR200Y resulting in plasmid pBADXerIR200Y/56X5’ containing a 200-bp 
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vpmaY-RS and a 56-bp vpmaX-RS as inverted repeats. Plasmid pBADXer53U5’/57Y5’ was obtained 
by replacing the NarI/ClaI and NsiI cloned 200-bp vpmaY RS of pBADXerIR57Y5’ with a 53-bp 
vpmaU-RS generated by annealing oligonucleotides OligoRSUsen and OligoRSUasen as described. 
The obtained fragment contained a MscI blunt end and a BstAPI overhang for cloning at the respective 
sites in plasmid pBADXerIR57Y5’ resulting in plasmid pBADXer53U5’/57Y5’ containing a 57-bp 
vpmaY-RS and a 53-bp vpmaU-RS as inverted repeats. 
Construction of plasmids pIL and pILDR. The lacZ gene with its native Shine-Dalgarno sequence 
from E. coli was obtained by PCR as described (see section PCR amplication). The BamHI- and SmaI-
cut 3.1 kb product was introduced into the corresponding sites present in the left IS element of 
transposon Tn4001mod in plasmid pISM2062 resulting in plasmid pIL. The 184-bp vpmaU-RS was 
amplified as described for the construction of pBADXer200Y/184U except that oligonucleotides 
184Ubfw (containing a BamHI site) and 184Unrv (containing a NcoI site) were used as primers. The 
BamHI- and NcoI-cut product was introduced into the corresponding sites of pIL resulting in vector 
pILRSU carrying the lacZ gene flanked by a 184-bp vpmaU RS at the 5’ end. The 200-bp vpmaY RS 
was amplified as described for construction of pBADXer200Y except that oligonucleotides 200YBfw 
and 200YBrv (both containing BglII sites) were used as primers. The PCR fragment restricted with 
BglII, was introduced into the BglII site of dephosphorylated plasmid pILRSU. The direct repeated 
orientation of this fragment was verified by sequencing. The resulting vector pILDR contained the 
lacZ gene flanked by a 184-bp vpmaU-RS at the 5’ end and a 200-bp vpmaY-RS at the 3’ end aligned 
as direct repeats. 
 
Restriction analysis and agarose gel electrophoresis of recombination products. Recombination 
products derived from plasmid pBADXerDR200Y containing direct repeated RS were applied directly 
on a 1% (w/v) agarose gel or after linearization with XbaI and HindIII restriction endonucleases. 
Inversion events within plasmids containing two inverted repeated RS (pBADRS21x2, 
pBADXerRS21x2, pBADXerIR200Y pBADXerIR21Y, pBADXerIR31Y3’, pBADXerIR56Y3’, 
pBADXerIR57Y5’, pBADXerIR111Y, pBADXer200Y/184U, pBADXerIR200Y/56X5’ and 
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pBADXer53U5’/57Y5’) were verified by applying the HindIII- and EcoRV-digested samples on a 1% 
(w/v) agarose gel and visualizing under UV light after ethidium bromide staining. 
 
RESULTS 
A conserved 21-bp sequence common to all vpma genes is sufficient for Xer1-mediated inversion. 
Alignment of the 5’ UTR region of all six vpma genes present in clone 55-5 of type strain PG2 
identified a conserved 21-bp region (TTGATATTTATTAATAGATTT) thought to be involved in 
Xer1-mediated recombination (10). To verify if this 21-bp RS is indeed involved and is sufficient for 
recombination, two inverted repeated 21-bp RS were introduced into plasmid pBAD24 together with 
the xer1 gene, which was placed under the transcriptional control of the arabinose promoter. The 
resulting plasmid pBADXerRS21x2 was introduced into E. coli, and recombination events were 
followed by testing the plasmid preparations obtained from samples removed after 6 and 20 h of xer1 
induction. Uninduced samples of overnight grown cells carrying pBADXerRS21x2 and cells carrying 
pBADRS21x2 lacking the xer1 gene served as negative controls. For detection of inversion products, 
first a restriction analysis method was used, whereby the plasmid DNA was digested using HindIII and 
EcoRV restriction endonucleases and observed for appearance of recombination products upon 
agarose gel electrophoresis. An inversion event between the two inverted repeated RS in 
pBADXerRS21x2 would place the HindIII site near the EcoRV site (Fig. 1A) and would result in the 
appearance of restriction fragments of 4.7 kb and 0.4 kb beside the two original non-recombined 
plasmid fragments of 3.4 kb and 1.7 kb if sufficient amount of recombined product is present after 
xer1 induction. However, using this restriction analysis method we could not detect any inversion 
products for both samples taken 6 and 20 h after xer1 induction (data not shown). To check if the 
inversion events between two 21-bp RS occur at levels much below the detection limit of the 
restriction analysis assay, a more sensitive three-primer PCR assay was developed (Fig. 1). Primer P1 
(anneals to a region of the araC gene) and primer P2 (anneals to a region of the bla gene) enable the 
amplification of a 1 kb ‘recombinant’ fragment only in case of an inversion between the two RS (Fig. 
1A), whereas primer P1 and primer P4 (anneals to a region between the pBR322 ori and the bla gene) 
enable the amplification of a 1.4 kb ‘non-recombinant’ product in the non-recombined vector serving 
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as an internal positive control in the PCR assay (Fig. 1A and 1B). Beside the 1.4 kb P1-P4 product, 
samples of pBADXerRS21x2 showed a 1 kb P1-P2 amplicon after 6- and 20-h of xer1 induction (Fig. 
1C, lanes 7 and 8) demonstrating that inversion has occurred between the two inverted repeated 21-bp 
RS. This 1 kb P1-P2 ‘recombinant’ amplicon was absent in the uninduced sample of 
pBADXerRS21x2 (Fig. 1C, lane 6) and in samples corresponding to the plasmid pBADRS21x2 (Fig. 
1C, lanes 3-5) that carries two inverted repeated 21-bp RS but lacks the xer1 gene, clearly 
demonstrating the role of Xer1 recombinase in mediating inversions at the 21-bp RS. As expected, 
these samples showed amplification of the 1.4 kb P1-P4 ‘non-recombinant’ control product. Also, no 
recombination was observed in a similar PCR experiment with a control plasmid construct where only 
one of the two 21-bp RS was present along with the xer1 gene (data not shown). Furthermore, the 1 kb 
P1-P2 ‘recombinant’ PCR product obtained with pBADXerRS21x2 when sequenced from both sides 
generated a sequence that correlates very well to the inversion having occurred at the 21-bp region, 
because the sequence corresponding to the HindIII site was evident in this 1 kb PCR product just next 
to the RS21 region when sequenced with the P2 primer, which is plausible only if the inversion has 
occurred in the 21-bp region. Hence, the above PCR and sequencing data are very consistent and 
indicate that the 21-bp region is sufficient for Xer1-mediated recombination and that this conserved 
region of the 5’ UTR of all vpma genes is most likely the site of cleavage and strand-exchange 
occurring during vpma gene inversions. 
  
vpma sequences flanking the conserved 21-bp RS enhance the amount of recombinant products 
to allow detection via restriction analysis assay. To assess if a larger RS would have an effect and 
improve the amounts of the inversion products such that they are visible during the restriction analysis 
assay described earlier, we constructed the plasmid pBADXerIR200Y (Fig. 2A). Two inverted 
repeated 200-bp RS, each constituting 152 bp of the 5’ UTR of the vpmaY gene including the 
conserved 21-bp region along with 48 bp of the coding sequence of vpmaY (Fig. 2C), were introduced 
into plasmid pBAD24 together with the xer1 recombinase gene. As described before, the inversions 
were studied after transformation into E. coli and upon xer1 induction. Uninduced samples of 
overnight grown cultures and samples taken before xer1 induction served as negative controls. 
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Induction of xer1 would result in inversion of the DNA fragment between the two RS, thereby placing 
the HindIII site near the EcoRV site (Fig. 2A). Restriction analysis (HindIII/EcoRV) of the samples 
removed after 2, 4 and 6 h of Xer1 induction clearly showed a 4.9 kb inversion fragment beside the 
two original non-recombined plasmid fragments of 3.6 kb and 1.9 kb (Fig. 2B, lanes 4-6). A similar 
inversion fragment could not be detected when the same amount of plasmid pBADXerRS21x2 
containing two 21-bp RS was used in a restriction assay alongside pBADXerIR200Y DNA (data not 
shown), thereby proving that additional sequences flanking the 21-bp conserved region are 
instrumental in improving the amounts of Xer1-mediated recombinant products. The second 
HindIII/EcoRV inversion fragment of pBADXerIR200Y, which is about 0.6 kb is not visible on the 
agarose gel in Fig. 2B (lanes 4-6) due to the cumulative effect of its small size and due to small 
amounts of recombination products present in the total plasmid preparation. The 4.9 kb 
HindIII/EcoRV inversion fragment is absent in the uninduced samples (Fig. 2B, lanes 2 and 3), 
whereas the intensity of this fragment shows a proportional increase with Xer1 induction starting from 
2 to 6 h (Fig. 2B, lanes 4-6). It was further confirmed by sequence analysis that the 4.9 kb 
HindIII/EcoRV fragment is indeed a product of an inversion event between the two 200-bp RS. These 
results indicate that sequences in the vicinity of the 21-bp RS improve the amounts of Xer1-mediated 
inversion products and lead to their detection in the restriction analysis assay, which was not possible 
with 21-bp RS without flanking sequences. 
  
The Xer1 recombinase mediates excision between direct repeated RS in E. coli. The outcome of a 
recombination event is determined by the alignment of the corresponding RS on a DNA segment (16). 
Inverted repeated RS enable inversion, whereas direct repeated RS result in excision of the interjacent 
DNA fragment (16). To analyze the effect of Xer1 recombinase on direct repeated RS in E. coli, 
plasmid pBADXerDR200Y was constructed (Fig. 3A). The xer1 gene was cloned alongside two 200-
bp RS (as depicted in Fig. 2C) identical to those used for inversion studies but this time aligned as 
direct repeats. Upon xer1 induction, the DNA sequence flanked by two direct repeated RS was excised 
and resulted in two excision products: a 3.2 kb replicative miniplasmid (mp) carrying the origin of 
replication besides the bla gene, and a non-replicative 2.3 kb minicircle (mc) carrying the residual 
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sequence (Fig. 3A). As seen in Figure 3B (lanes 4-7), the supercoiled (sc) forms of the two 
recombination products (sc mp and sc mc) are visible after 2, 4 and 6 h of xer1 induction along with 
the original unrecombined plasmid (sc op). The samples were linearized using XbaI and HindIII 
restriction enzymes to further confirm the sizes of the various plasmids. The 5.5 kb original 
unrecombined plasmid is visible in all samples, both uninduced and induced, whereas the excision 
products corresponding to the 3.2 kb miniplasmid and 2.3 kb minicircle are visible only upon xer1 
induction (Fig. 3C, lanes 4-7). 
  
Sequences flanking the conserved 21-bp region at the 5’ end are required for higher amounts of 
recombination products. Our results indicate that the 21-bp region, identical in the 5’ UTR of all six 
vpma genes, is sufficient for recombination, although a sensitive PCR-based assay is required to verify 
such site-specific recombinations. On the other hand, inversion between two 200-bp RS including the 
21-bp region and additional flanking nucleotides allowed visualization of recombination via the 
restriction analysis method, indicating that a larger RS favours higher amounts of recombination 
products. In order to shorten this 200-bp RS and to know if 5’ or/and 3’ flanking regions of the 
conserved 21-bp region are critical for the detection of sufficient amounts of recombination products, 
the restriction analysis method was performed using newly constructed plasmids (pBADXerIR21Y, 
pBADXerIR31Y3’, pBADXerIR56Y3’, pBADXerIR57Y5’ and pBADXerIR111Y), where one of the 
two 200-bp RS of plasmid pBADXerIR200Y was successively replaced by shorter versions of 
different lengths and different flanking regions derived from the vpmaY gene as depicted in Fig. 4A. 
Inversion products between the 200-bp RS and the 21-bp RS in pBADXerIR21Y could not be detected 
in the restriction analysis method even after 20 h of xer1 induction (Fig. 4B, lane 4), which confirms 
our previous results using pBADXerRS21x2 (carrying two 21-bp RS) and acts as a negative control 
while comparing it with other constructs. Also, extension of the 21-bp region by 10 nucleotides in 
pBADXerIR31Y3’ (Fig. 4A, RS31Y3’) and 35 nucleotides in pBADXerIR56Y3’ (Fig. 4A, RS56Y3’) 
at the 3’ end did not yield any recombination products as seen in Fig. 4B, lanes 5 and 6, respectively. 
However, addition of 54 nucleotides at the 3’ end and 36 nucleotides at the 5’ end of the 21-bp region 
in pBADXerIR111Y (Fig. 4A, RS 111Y) allowed detection of recombination products after restriction 
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analysis (Fig. 4B, lane 7). Having compared this positive result with that of pBADXerIR56Y3’ (Fig. 
4A, RS56Y3’) which was negative for recombination, one of the obvious difference between the two 
constructs was the presence of additional 36 nucleotides flanking the 21-bp region at the 5’ end. Based 
on these results, we constructed pBADXerIR57Y5’ (Fig. 4A, RS57Y5’), where the 57-bp RS 
consisted of 21-bp conserved region flanked by additional 36 bp at the 5’ end. Indeed, when analyzed 
by the restriction assay, pBADXerIR57Y5’ exhibited detectable amounts of inversion products (Fig. 
4B, lane 8). Taken together, these data clearly illustrate that the recombination events mediated by 
Xer1 recombinase are enhanced by sequences flanking the conserved 21-bp RS at the 5’ end. 
  
Recombination events between RS derived from different vpma genes. While the 21-bp RS 
sequence is completely conserved in the 5’ UTR of all six vpma genes, the 5’ flanking regions do not 
show significant homology within different vpma genes (10). Our previous results focused on 
recombination events between two RS that originated from the 5’ UTR of the same gene, namely 
vpmaY. However, two vpmaY RS do not reflect the native alignment of (vpma) RS in the M. 
agalactiae vpma locus, where Xer1-mediated recombination occurs within the RS of two different 
vpma genes rather than that of the same vpma gene. VpmaY was shown to be expressed in M. 
agalactiae clone 55-5, a clonal variant of the type strain PG2 (10, 11), where the vpmaY gene is 
located downstream of the unique vpma promoter and therefore constitutes the expressed vpma gene. 
Our previous results indicated that a region of 36 bp flanking the 21-bp conserved sequence at the 5’ 
end are required for the detection of Xer1-mediated inversion products via restriction analysis method 
after 20 h of xer1 induction (Fig. 4B, lane 8). This 36-bp region is specific to the 5’ UTR of the 
expressed vpmaY gene, and has no sequence homology with the 5’ UTR of all other unexpressed vpma 
genes. As in pBADXerIR200Y both 200-bp RS originated from the 5’ UTR of the expressed vpmaY 
gene, this configuration does not correspond with the actual recombination scenario that might be 
operating in the vpma locus of M. agalactiae. Inversions within the vpma locus occur between two 
inverted repeated RS of different vpma genes sharing the 21-bp region but have different nucleotides 
flanking this region at the 5’ end. In order to verify if the two RS originating from different vpma 
genes also show similar results in the restriction analysis method, plasmid constructs carrying RS from 
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different vpma genes (Fig. 5) were constructed for further recombination experiments: in the first 
construct, namely pBADXerIR200Y/184U, one of the two vpmaY 200-bp RS within 
pBADXerIR200Y was replaced by a 184-bp vpmaU sequence (RS184U, Fig. 5A). As expected, 
inversions were detected after restriction analysis and gel electrophoresis of samples removed after 20 
h of induction (Fig. 5B, lane 4). Similar inversion products were observed with construct 
pBADXerIR200Y/56X5’ (Fig. 5B, lane 5) carrying a 200-bp vpmaY RS and a 56-bp RS of the vpmaX 
gene which covers the conserved 21-bp region and 35 bp flanking it at the 5’ end (RS56X5’, Fig. 5A). 
So far, all these inversions were observed in constructs where at least one of the RS was the 200-bp 
vpmaY RS. To verify if such inversions can be detected by restriction analysis even for those plasmids 
where both 200-bp vpmaY-RS are replaced by shorter versions, we constructed 
pBADXerIR53U5’/57Y5’. Here, a 57-bp vpmaY-RS, where the 21-bp region is extended by 36 bp at 
the 5’end (RS57Y5’, Fig. 5A), and a 53-bp vpmaU-RS containing the 21 bp-region and 32 bp flanking 
it at the 5’ end (RS53U5’, Fig. 5A), were introduced alongside the xer1 gene. When subjected to 
induction and restriction analysis, an inversion band of 4.6 kb was visible (Fig. 5B, lane 6). Such 
inversions between vpmaU-RS / vpmaY-RS and vpmaX-RS / vpmaY-RS not only reflect the 
recombination events actually operational in the vpma locus of the native M. agalactiae system, but 
also confirm our earlier results showing that the 5’ flanking region of the 21-bp RS is indeed 
responsible for enhanced accumulation of recombination products. 
 
Xer1 can mediate excisions between vpma RS in M. agalactiae. Having demonstrated excisions in 
E. coli by cloning two 200-bp vpmaY RS as direct repeats in plasmid pBADXerDR200Y (Fig. 3), the 
next step was to analyze if such excisions can occur in M. agalactiae. Since vpma genes are present in 
both orientations in the native vpma gene locus of M. agalactiae (4, 10), excisions between the direct 
repeated vpma RS are theoretically possible via the chromosomally encoded Xer1 recombinase. For 
analysing such excision events in the native M. agalactiae system, we developed a lacZ-based reporter 
system which was used to demonstrate Xer1-mediated excisions in M. agalactiae based on blue/white 
selection, as well by PCR analysis. The lacZ gene with its native Shine-Dalgarno sequence from E. 
coli was introduced into the left IS element of transposon Tn4001mod in pISM2062 (22) resulting in 
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recombinant plasmid pIL. Transformation of pIL into the wild-type M. agalactiae strain PG2, as well 
as into the xer1-disrupted PLMY (4) resulted in blue transformant colonies on SP4 agar plates 
supplemented with X-Gal (Fig. 6C). Interestingly, lacZ expression did not require the addition of a 
native promoter element upstream of the lacZ sequence indicating that transcription was driven by a 
transposon-based promoter. After this successful demonstration of lacZ as a reporter gene in M. 
agalactiae, plasmid pILDR (Fig. 6A) was constructed in which the promoterless lacZ gene was 
flanked by a vpmaU-derived RS184U (Fig. 5A) at the 5’ end and a vpmaY-derived RS200Y (Fig. 5A) 
at the 3’ end, with both RS elements aligned as direct repeats. Transformation of pILDR into wild type 
PG2 strain indeed resulted in white colonies (Fig. 6C), as the lacZ gene was excised from the pILDR 
due to an excision event between the direct repeated vpmaY- and vpmaU-RS mediated by the 
chromosomal Xer1 recombinase (Fig. 6B). Transpositional integration of pILDR was confirmed in 
these white clones by Southern hybridization (data not shown) using a Tn-specific probe as described 
earlier (5). In contrast, pILDR transformants in the xer1-disrupted mutant strain PLMY still exhibited 
a faint blue-colony phenotype (Fig. 6C), as they lacked Xer1 recombinase to accomplish a similar lacZ 
excision (Fig. 6B). However, compared to the pIL transformants of PG2 and PLMY, these colonies 
showed reduced intensity of blue color (Fig. 6C). This might be due to the introduction of an extra 
184-bp vpmaU-RS sequence upstream of the promoterless lacZ gene which leads to lower levels of 
lacZ transcription due to increased distance from the transposon promoter. These Xer1-mediated 
excisions were further confirmed by PCR analysis using primer 184Ubfw which anneals to the 184-bp 
vpmaU-RS, and primer ISR-f that anneals to a region upstream to the left IS element of Tn4001mod 
(Fig. 6B). Since, both primers anneal outside the region of recombination, the amplified product would 
verify the absence or presence of a lacZ gene excision event. As expected, PCR reactions using 
genomic DNA of PLMY transformed with pILDR resulted in amplification of just a single fragment 
of 3.5 kb (Fig. 6D, lane 3) corresponding to the unexcised lacZ sequence flanked by the two RS, 
indicating that no excision has occurred in this xer1-disruptant strain. On the contrary, a similar PCR 
reaction performed with genomic DNA obtained from pILDR PG2 transformants showed an 
additional band of 245-bp (Fig. 6D, lane 4) corresponding to the shortened sequence created after 
Xer1-mediated recombination of the vpmaU- and vpmaY-RS that leads to the deletion of the 
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interjacent lacZ gene (Fig. 6B). Furthermore, sequencing of the 245-bp product displayed an expected 
hybrid site (RSUY), comprising the 5’ region of the vpmaU-RS, the 21-bp consensus sequence 
common for both RS, and the 3’ region of the vpmaY RS. These results clearly demonstrated that 
Xer1-mediated excisions between direct repeated vpma-RS are feasible in M. agalactiae. The above 
data not only provide the first experimental proof of the lacZ reporter system being functional in M. 
agalactiae, but also confirm our earlier postulates regarding the Xer1 recombination system based on 
the results of the recombination experiments done in E. coli. 
 
DISCUSSION 
The results demonstrate that a consensus sequence (TTGATATTTATTAATAGATTT) of 21 bp 
present in the 5’ UTR of all vpma genes is sufficient for Xer1-mediated inversion and that 
recombinational strand exchange occurs within this region. In site-specific recombination systems, 
core-RS constitute DNA sequences where recombinase binding and strand exchange take place. 
Typically, these core-RS regions exhibit dyad symmetry as two perfect or imperfect inverted repeats 
(11-13 bp) which act as recombinase binding elements surrounding a 6-8 bp overlap sequence within 
which strand cutting and exchange occurs (7, 12, 24). Alignment of the 21-bp RS of M. agalactiae 
with its reverse and complemented sequence identified an 8-bp palindromic central sequence 
(TATTAATA) but did not reveal any other significant dyad symmetry (Fig. 7). However, if the first 3 
bases of the 21-bp site are excluded, similar alignment reveals an impressive level of dyad symmetry 
flanking the central 8-bp palindrome (Fig. 7). Generally, overlap sequences are non-palindromic and 
for the simplest site-specific recombination systems of the λ-integrase family, exemplified by the Cre 
recombinase of bacteriophage P1 and the Flp recombinase of Saccharomyces cerevisiae, this 
asymmetry is sufficient to provide polarity to the site (7). It has been well demonstrated that 
conversion of an asymmetric overlap region to a symmetric one leads to recombination events that 
have no polarity. A pair of such symmetric sites when placed on a DNA molecule, led to both 
excisions and inversions independent of their orientation as direct or inverted repeats (17, 29).  
RS sequences involved in site-specific recombination systems of mycoplasmas show different levels 
of dyad symmetry. In M. pulmonis, the site-specific HvsR recombinase catalyzes inversions at two 
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distinct loci causing variation in the production of restriction-modification enzymes (hsd locus), as 
well as phase variation of surface lipoproteins (vsa locus). Comparison of the RS of these two 
different loci revealed no significant sequence similarity, where the dyad symmetry was very weak for 
vsa RS compared to the hsd RS (31). Recent studies in M. penetrans have demonstrated that site-
specific recombination mediates mpl promoter inversions causing phase variation of individual mpl 
lipoprotein genes. When compared with RS of other site-specific recombinases, these inversions occur 
within a considerably short 12-bp inverted repeated sequence flanking the promoter region. Also, 
comparison of the inverted repeated sequence of individual mpl promoters revealed a consensus 
sequence of TAAYNNNDATTA, where nucleotides TAA and ATTA at both ends of the inverted 
repeated sequence resemble a dyad motif, whereas the central region differs from each other and might 
be responsible for preventing inappropriate recombination between different mpl promoters or for 
differences in the inversion frequencies of individual promoters (18). In general, it appears that the RS 
sequences of site-specific recombination systems of mycoplasmas do not exhibit comparable dyad 
symmetry as shown for other well-characterized site-specific recombination systems, and so it is 
difficult to predict the point of strand exchange and recombinase binding. Since several RS have been 
characterized in mycoplasmas, identification of binding sites for recombinase enzymes and detection 
of the crossover region involved during strand exchange may be instrumental for further 
understanding of such recombination reactions. 
In vivo inversion experiments in E. coli using vpma-RS from the same, as well as from different vpma 
genes revealed that Xer1 can act in trans, and that additional nucleotides flanking the conserved 21-bp 
region at the 5’ end lead to enhanced accumulation of  recombination products. Indeed, many site-
specific recombination systems require additional elements beyond the core-RS which typically 
include extra binding sites for the recombinase or accessory proteins required for efficient 
recombination (24). However, comparison of the 5’ flanking nucleotides of the vpma-RS does not 
show any significant sequence identity among different vpma RS, except a box of 3 nucleotides (ATA) 
located 13-15 bases upstream of the 21-bp region. Comparing individual 5’ flanking regions with each 
other shows sequence identity levels of up to 82.1% (including the 21-bp RS common for all vpma 
genes). Future studies may concentrate on the evaluation of inversion frequencies between the RS of 
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different vpma genes to assess if homology in this region is required to enhance the rate of 
recombination. 
The newly developed excision assay based on the lacZ reporter gene successfully demonstrated 
excision events between two direct repeated vpma-RS in the M. agalactiae type strain PG2. The same 
orientation of vpma genes in the vpma locus (10) leads to direct repeated orientation of the RS, and 
any excision events between them would result in deletion of genetic material, including not only the 
vpma genes but also the unique vpma promoter, which is the key element for expression of these 
variable surface proteins. This might be critical for the survival of the pathogen in the host and 
resultant clones with shorter excised versions of the vpma locus might be selected against due to 
reduced fitness potential. Based on their result that some PG2 clones yield a very low proportion of 
smaller vpma fragments in addition to a high proportion of expected full-length amplicons during PCR 
amplification of the whole vpma locus, Glew et al (2002) have previously suggested that such 
excisions occur at a low frequency (10). Whether additional regulatory factors, as found in other 
bacterial site-specific recombination systems (2, 6, 16, 24, 30), control and favour vpma inversions 
above their excisions needs to be elucidated. Considering the minimal genome of M. agalactiae, it is 
possible that such stochastic excisions in a proportion of population could be the cost that the pathogen 
pays to maintain this antigenic variation machinery for overall population advantage.  
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FIGURE LEGENDS 
FIG. 1. A three-primer PCR inversion assay for the detection of inversions within the two 21-bp RS 
conserved in the 5’ UTR of all vpma genes. (A) Schematic representation of inversion of plasmid 
pBADXerRS21x2 carrying two inverted repeated 21-bp RS (RS21, indicated by bold black arrows) 
along with the xer1 gene, shown in comparison with (B) plasmid pBADRS21x2, which carries the 
same RS but cannot undergo inversions as it lacks a xer1 gene and thus acts as a negative control. 
Primers P1, P2 and P4 annealing to the araC sequence (regulatory gene of L-arabinose operon), the 
bla sequence (ampicillin resistance gene) and the region adjacent to the ori (pBR322 origin), 
respectively, are indicated by thin black arrows. (C) Agarose gel electrophoresis of PCR products at 
different stages of arabinose induction. Presence of a 1 kb P1-P2 amplicon corresponds to inversion 
events in E.coli between the two RS21 sequences only upon Xer1 induction at 6 and 20 h (lanes 7 and 
8) for pBADXerRS21x2, and is absent for the uninduced overnight sample (lane 6). The latter, as well 
as both the induced (lanes 4 and 5) and uninduced (lane 3) samples of control plasmid pBADRS21x2, 
show only the 1.4 kb P1-P4 product amplified from the sequence of unrecombined plasmids. Lane 2: 
No DNA template control; Lanes 1 and 9: molecular size marker (1 kb ladder, Invitrogen). 
 
FIG. 2. Restriction analysis of the inversion events occurring between two inverted repeated 200-bp 
RS in E. coli. (A) Schematic representation of inversion of plasmid pBADXerIR200Y carrying two 
inverted repeated 200-bp RS (RS200Y, indicated by bold black arrows) along with the xer1 gene 
(white arrow). Induction of xer1 results in inversion of the DNA fragment flanked by the two RS200Y 
resulting in plasmid pBADXerIR200Y IV where the HindIII and EcoRV sites are located close to each 
other. ori, pBR322 origin; bla, ampicillin resistance gene; araC, regulatory gene of L-arabinose 
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operon. (B) Agarose gel electrophoresis of HindIII- and EcoRV-digested recombination products 
obtained at different time points. Two fragments of 3.6 kb (OP1) and 1.9 kb (OP2) that correspond to 
the original unrecombined plasmid are present in all samples. An inversion fragment of 4.9 kb (IV) is 
visible after 2 h (lane 4), 4 h (lane 5) and 6 h (lane 6) of xer1 induction, whereas it is absent in the 
uninduced cells grown overnight (lane 2) and in the sample taken at the start of induction (lane 3). 
Lanes 1 and 7: molecular size marker (1 kb ladder, Invitrogen). (C) Sequence of the RS200Y fragment 
obtained from the vpmaY gene of M. agalactiae. The bold letters represent the 21-bp conserved 
sequence found in the 5’ UTR of all vpma genes. 
 
FIG. 3. Xer1 mediates excisions between two 200-bp RS. (A) Schematic representation of excision of 
plasmid pBADXerDR200Y carrying two direct repeated 200-bp RS (RS200Y, indicated by bold black 
arrows) along with the xer1 gene (white arrow). Induction of xer1 results in excision of the DNA-
fragment flanked by the two direct repeated RS200Y resulting in two recombination products: 
miniplasmid (mp) and minicircle (mc). ori, pBR322 origin; bla, ampicillin resistance gene; araC, 
regulatory gene of L-arabinose operon. (B) An inverted image of agarose gel electrophoresis of 
supercoiled (sc) recombination products. Supercoiled miniplasmid (sc mp) and supercoiled minicircle 
(sc mc) are visible 2 h (lane 4), 4 h (lane 5) and 6 h (lane 6) after xer1 induction beside the band 
corresponding to the unrecombined original plasmid (sc op). Recombination products are not visible in 
the uninduced cells grown overnight (on, lane 2) and in the sample taken at the start of induction (0h, 
lane 3). Lanes 1 and 7: molecular size marker (1 kb ladder, Invitrogen). (C) An inverted image of 
agarose gel electrophoresis of HindIII- and XbaI-linearized (lin) recombination products confirms the 
sizes of the original unrecombined plasmid pBADXerDR200Y (X/H op, 5.5 kb) and the minicircle 
and miniplasmid (lin mc, 2.3 kb and lin mp, 3.2 kb) excised out of it upon xer1 induction. Lanes 1 and 
7: molecular size marker (1 kb ladder, Invitrogen). 
 
FIG. 4. Sequences flanking the 21-bp RS at the 5’ end enhance the amount of Xer1 inversion products. 
One of the two 200-bp vpmaY RS in pBADXerIR200Y was replaced by shorter versions of different 
lengths and flanking regions, namely RS21Y (in pBADXerIR21Y, the white box represents the 21-bp 
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conserved 5' UTR), RS31Y3’ (in pBADXerIR31Y3’), RS56Y3’ (in pBADXerIR56Y3’), RS111Y (in 
pBADXerIR111Y), and RS57Y5’ (in pBADXerIR57Y5’) (A) to determine the minimal RS which 
gives detectable amounts of inversion products (IV) during restriction analysis and agarose gel 
electrophoresis (B). Samples were digested with HindIII and EcoRV after 20 h of xer1 induction. 
Plasmid pBADXerIR200Y showed a 4.9 kb inversion band between 200Y/200Y RS after induction 
(lane 3) and served as a positive control, whereas its uninduced overnight sample was negative for an 
inversion band (lane 2) and only showed bands that correspond to the unrecombined parent plasmid 
(OP1 and OP2). Similarly, no inversion was detectable between 200Y/21Y RS (lane 4), 200Y/31Y3’ 
RS (lane 5) and 200Y/56Y3’ RS (lane 6), whereas appearance of 4.8 kb (lane 7) and 4.75 kb (lane 8) 
bands indicate inversion events between 200Y/111Y RS and 200Y/57Y5’, respectively. Lanes 1 and 
9: molecular size marker (1 kb ladder, Invitrogen). 
 
FIG. 5. Inversion events between different vpma RS. Plasmids carrying RS sequences derived from 
two different vpma genes were constructed to reflect the native recombination events operative in M. 
agalactiae, and transformed into E. coli to check for inversion events. (A) Schematic representation of 
the RS elements used in the different plasmid constructs: RS200Y and RS57Y5' (from vpmaY), 
RS184U and RS53U5' (from vpmaU) and RS56X5' (from vpmaX); white box depicts the 21-bp 
conserved region (B) Agarose gel electrophoresis of HindIII and EcoRV digests of different samples 
removed after 20 h of xer1 induction. The inversion bands (IV) and the bands corresponding to the 
original unrecombined plasmid (OP1 and OP2) are indicated on the left margin. Plasmid 
pBADXerIR200Y showed a 4.9 kb inversion band between 200Y/200Y RS after induction (lane 3) 
and served as a positive control, whereas its uninduced overnight sample was negative for an inversion 
band (lane 2) and only showed bands that correspond to the unrecombined parent plasmid (OP1 and 
OP2). Inversion bands of 4.9 kb (lane 4), 4.75 kb (lane 5) and 4.6 kb (lane 6) were respectively 
observed for the newly constructed pBADXerIR200Y/184U, pBADXerIR200Y/56X5’ and 
pBADXerIR53U5’/57Y5’ plasmids where the two RS originated from different vpma genes as 
indicated. Lanes 1 and 7: molecular size marker (1 kb ladder, Invitrogen). 
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FIG. 6. Demonstration of Xer1-mediated excisions in M. agalactiae. (A) Illustration of plasmid 
pILDR used for studying Xer1-mediated excisions in M. agalactiae: the lacZ gene is flanked by a 184-
bp vpmaU RS and a 200-bp vpmaY RS (RS184U and RS200Y, respectively, black arrowheads) 
aligned as direct repeats within the left Insertion Sequence of transposon Tn4001mod (IS256L). ori, 
pBR322 origin; bla, ampicillin resistance gene; gm, gentamicin resistance gene. (B) Schematic 
representation of the genomic integration of pILDR in M. agalactiae type strain PG2 (PG2 pILDR) 
and the xer1-disruptant PLMY (PLMY pILDR): Xer1 recombinase (white ellipse) mediates excision 
between RS184U and RS200Y resulting in deletion of the interjacent lacZ sequence in PG2, but not in 
PLMY. Primers 184Ubfw and ISR-f (thin black arrows) used for detecting excisions via PCR and their 
corresponding amplicons (thin black lines) are indicated for both PG2 and PLMY. (C) Colony 
phenotype of lacZ transformants: parent plasmid pIL, which carries the lacZ gene without direct 
repeated RS (not shown), when transformed into PG2 (PG2 pIL) and PLMY (PLMY pIL) resulted in 
intense blue colonies on SP4 agar plates containing X-Gal. Introduction of plasmid pILDR in PG2 
(PG2 pILDR) displayed white colonies, indicating that the lacZ gene was lost by site-specific excision 
between the direct repeated RS mediated by the M. agalactiae-encoded Xer1 recombinase (see Fig. 
6B). In contrast, excision is absent in the xer1-mutant PLMY indicated by blue colony formation 
(PLMY pILDR). (D) Agarose gel electrophoresis of PCR reactions verifying excision events in M. 
agalactiae: Primers 184Ubfw and ISR-f (indicated in Fig. 6B), both annealing outside the region of 
recombination, were used to detect excision of the lacZ gene. Genomic DNA of PLMY pILDR (lane 
3) enables amplification of only a 3.5 kb fragment, corresponding to the lacZ sequence, whereas PCR 
reactions using genomic DNA of PG2 pILDR transformants (lane 4) also displayed a 245-bp excision 
fragment corresponding to the hybrid RSUY created after excison between RS184U and RS200Y, in 
addition to the 3.5 kb lacZ fragment. Lane 2: No DNA template control. Lanes 1 and 5: molecular size 
marker (1 kb ladder, Invitrogen). 
 
FIG. 7. Dyad symmetry in the 21-bp sequence conserved in the 5' UTR of vpma genes. (A) Nucleotide 
sequence of the conserved 21-bp region, and (B) the aligned sequence of  21-bp and 18-bp regions 
(where the first three nucleotides of 21 bp are excluded) with the respective reverse complemented 
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sequence. The central palindromic sequence is in bold letters and regions with dyad symmetry are 
indicated by asterisks.  
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5.2 Collection of Data: Xer1-independent Mechanisms of Vpma Phase Variation are 
Triggered by the Presence of Vpma-specific Antibodies  
INTRODUCTION 
Mycoplasma agalactiae, the main etiologic agent of the syndrome Contagious Agalactia in sheep and 
goats, exhibits high-frequency antigenic variation of its major immunodominant surface lipoproteins, 
the so-called Vpmas (variable proteins of M. agalactiae) (Flitman-Tene et al., 2003; Glew et al., 2000; 
2002). Six vpma genes, encoded by the pathogenicity island-like vpma multigene locus, were 
demonstrated to undergo phase variation by specific DNA inversions mediated by a site-specifc 
recombinase (Xer1) of the λ-integrase family encoded adjacent to the vpma genes (Flitman-Tene et al., 
2003; Glew et al., 2000; 2002). Functional knock-out of the xer1 gene in the M. agalactiae type strain 
PG2 has clearly demonstrated that Xer1 recombinase is essential for site-specific recombinations 
within the vpma locus (Chopra-Dewasthaly et al., 2008). In the xer1-disrupted Vpma phase-locked  
mutants (PLMs) further vpma switching by site-specific DNA inversions was abolished and cells were 
locked in an expression phase where only one vpma gene is steadily expressed (Chopra-Dewasthaly et 
al., 2008).  
The aim of the present study was to evaluate if Xer1-independent mechanism may provide an 
additional level of Vpma antigenic diversity in the M. agalactiae type strain PG2 to survive in the 
animal host in absence of Xer1-mediated vpma inversions. Previously, our group had performed an 
experimental infection of sheep using a mixture of two PLMs, namely PLMU and PLMY (manuscript 
in preparation). Screening of the Vpma expression patterns of two clones isolated from the animals 
revealed that PLMs, which were stable for several generations in vitro had undergone Vpma 
switching. Genomic characterization of the vpma gene profiles of both clones demonstrated that DNA 
rearrangements other than Xer1-mediated site-specific inversions occurred in the vpma locus, 
including the generation of hybrid vpma genes, as well as vpma gene duplication and deletion, which 
lead to altered Vpma phenotypes. Recent studies on the M. agalactiae field strain 5632 have also 
identified some vpma genes displaying a mosaic structure, which are most likely results of similar 
recombination events (Nouvel et al., 2009). 
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For a limited number of Mycoplasma species, in vitro assays have been used to know if specific 
antibodies directed towards predominantly expressed surface antigens cause variability of the same as 
a result of immune pressure. In the bovine pathogen M. bovis it was demonstrated that monoclonal 
antibodies directed towards the major variable surface antigens (Vsps), as well as serum antibodies 
from immunized or experimentally infected calves can repress expression of the target proteins or 
induce switching to antigenically different proteins (Le Grand et al., 1996). In M. hyorhinis immune 
pressure assays were useful to evaluate the role of Vlp surface proteins in determining susceptibility to 
growth inihibitory effects of host antibodies (Citti et al., 1997). Similarly, cultivation of M. hominis in 
the presence of monoclonal antibodies directed against the 135-kDa surface exposed antigen Lmp1 led 
to the selection of escape mutants that were shown to contain deletions of repetitive domains within 
the corresponding lmp1 gene. However, these mutations were reported to be associated with 
spontaneous agglutination events, indicating that repetitive domains of Lmp1 may be important for 
repulsion of cells (Jensen et al., 1995).  
In order to know if Vpma-specific antibodies are the factors that trigger Vpma switching in M. 
agalactiae, and especially to test the hypothesis that Xer1-independent Vpma phenotypic changes 
were induced and selected by the immune defences of the host, we designed an immune pressure assay 
to reconstruct the results obtained from the animal experiments. Briefly, two PG2 derived strains, the 
clonal variant 55-5 predominantly expressing VpmaY (Glew et al., 2000; 2002) and the VpmaY 
expressing xer1-deficient mutant PLMY, which is unable to undergo further Vpma switching (Chopra-
Dewasthaly et al., 2008), were cultivated in the presence of a complement inactivated monospecific 
rabbit polyclonal antibody (pAb) recognizing the VpmaY protein (Chopra-Dewasthaly et al., 2008). In 
the presence of the α-Y pAb immune pressure, both strains were able to switch Vpma phenotypes 
although to very different extents and using different molecular mechanisms. As expected, high-
frequency Vpma switching in the wild-type strain 55-5 is governed by Xer1-mediated site-specific 
inversions, whereas strain PLMY tries to overcome this immune pressure by a low frequency Xer1-
independent mechanism resulting in the generation of novel hybrid vpma gene variants. Similar 
mechanism and vpma hybrids were also demonstrated for the xer1-disrupted clones isolated from 
animals after an experimental infection with PLMs (manuscript in preparation). Together, these results 
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clearly demonstrate that Xer1-independent vpma recombinations occur both in vitro, as well as in vivo 
in the M. agalactiae type strain PG2 and mediate Vpma surface variation under selection pressure of 
the host-induced immune response. 
 
MATERIALS AND METHODS 
Bacterial strains and culture conditions. In this study the M. agalactiae type strain PG2 (Solsona et 
al., 1996), the PG2 derived clonal variant 55-5 (Glew et al., 2000) and the xer1-deficient mutants 
PLMY and PLMU (Chopra-Dewasthaly et al., 2008) were used. PG2 and 55-5 were propagated at 
37°C in modified SP4 broth and agar plates (Chopra-Dewasthaly et al., 2005). For cultivation of 
PLMs, SP4 was supplemented with tetracycline at a concentration of 2 µg ml-1. 
 
Immune pressure assay. Exponential phase cultures of 55-5 and PLMY (approximately 109 CFU/ml) 
were ten-fold serially diluted to achieve cultures with approximately 106 CFU/ml. To 180 µl of the 
diluted culture 20 µl of heat-inactivated (56°C for 30 min) α-Y pAb (Chopra-Dewasthaly et al., 2008) 
was added (10% [vol/vol] concentration in standard medium). Control samples contained 20 µl PBS 
instead of the pAb. Cultures were incubated for 10 days at 37°C. To monitor growth, aliquots of 
cultures were plated at different time points on SP4 agar plates. CFU values were estimated by 
counting colonies under the stereomicroscope (Nikon). Mean CFU/ml values were calculated from 
three independent experiments. 
 
Colony immunoblot and Western blot analysis. Screening of the Vpma expression patterns was 
carried out by colony immunoblot analysis essentially as described elsewhere (Chopra-Dewasthaly et 
al., 2008). Briefly, nitrocellulose membranes were placed on the freshly grown colonies on agar plates 
for 5 min, detached and washed two times in TBS buffer (10 mM Tris, 154 mM NaCl, pH 7.4) before 
an overnight incubation at 4°C in pAb specific for the VpmaY protein (Chopra-Dewasthaly et al., 
2008). After three washing steps in TBS buffer containing 0.05% Tween 20 (Roth) for 10 min each, 
membranes were incubated for 2 h at room temperature in 1:2000 diluted swine anti-rabbit IgG 
conjugated to horseradish peroxidase (DakoCytomation, Denmark). After three washing steps in TBS 
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buffer, blots were developed in 4-chloro-1-naphthol (Bio-Rad) and hydrogen peroxide. The reaction 
was stopped after 20 min by washing membranes in water. 
Western blotting was accomplished by standard sodium dodecylsulphate-polyacrylamide gel 
electrophoresis using whole cell extracts of M. agalactiae cultures as described previously (Chopra-
Dewasthaly et al., 2008). Cell pellets were resuspended in PBS and boiled at 95°C for 5 min under 
reducing conditions. Proteins were separated in 10% polyacrylamide gels containing 3% (w/v) urea. 
Proteins were electrophoretically transferred to nitrocellulose membranes (Roth) using blotting buffer 
(48 mM Tris, 39 mM Glycine, 0.037% SDS and 20% Methanol) and immunostained by the same 
protocol as described for colony immunoblots. 
 
PCR reactions, DNA manipulation and Southern hybridization. Digoxigenin (DIG)-labeling 
(Roche) of vpma-specific gene probes by PCR was carried out according to the manufacturer’s 
recommendations using PG2 genomic DNA as template and a set of following primer pairs 
(oligonucleotides are summarized in Table 1) for individual vpma-specific gene probes: U2F and 
Urev1 (vpmaU), C1F and C1R (vpmaV), WDIGfw and WDIGrv (vpmaW), X1F and X1R (vpmaX), 
Y3F and Y3R (vpmaY), Z1F and Z2R (vpmaZ). PCR cycling conditions were as follows: 1 cycle of 
initial denaturation for 3 min at 94°C, 30 cycles of 95°C for 1 min, 57°C (vpmaU, vpmaV, vpmaX, 
vpmaY, vpmaZ) or 65°C (vpmaW) for 1 min, followed by 30s (vpmaU, vpmaV , vpmaX, vpmaY, 
vpmaZ) or 1 min (vpmaW) at 72°C and a final extension step for 5 min at 72°C. 
Mycoplasma genomic DNA was isolated by the method described previously (Chopra-Dewasthaly et 
al., 2005). For vpma-specific Southern blots genomic DNA was cut with appropriate restriction 
endonucleases: HindIII for hybridization with vpmaW-specific probe, HindIII and XbaI for vpmaU-, 
vpmaV-, vpmaX- and vpmaZ-specific probes and PstI for vpmaY-specific probe. Digested DNA was 
subjected to agarose gel electrophoresis and DNA fragments were transferred to nylon membranes 
(Roth) using a standard protocol (Sambrook et al., 1989). Hybridization with DIG-labeled probes and 
washing under stringent conditions followed by non-radioactive detection was carried out according to 
the manufacturer’s recommendations (Roche). Southern blot analysis confirming xer1-disruption was 
carried out as described previously (Chopra-Dewasthaly et al., 2008). 
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Cloning and sequencing of vpma loci. In order to define the vpma configuration of the escape 
variants PLM18, PLM16 and X-EV, ClaI digested genomic DNA was self ligated and transformed 
into E. coli DH10B as described (Chopra-Dewasthaly et al., 2008). Tetracycline and ampicillin-
resistant transformants were isolated and subjected to restriction and PCR analysis. Plasmid 
preparations of recombinant plasmids were used for DNA sequencing. Sequencing was carried out by 
LGC Genomics (Germany). Primers used for sequencing are summarized in Table 1. 
 
RESULTS AND DISCUSSION 
PLMs switch over to new Vpma phenotypes in the native host via Xer1-independent 
mechanisms. 
Generation of xer1-deficient PLMs has greatly facilitated the possibilty not only to study the role of 
individual Vpma proteins but also of alternative Vpma switching mechanisms which might act in the 
absence of the Xer1 recombinase (Chopra-Dewasthaly et al., 2008). To address this issue, previously 
an equimolar mixture of two PLMs (PLMU and PLMY) was used in an experimental infection of 
sheep. Initial vpma gene configuration of both PLMY and PLMU is demonstrated in Fig. 1A whereby 
the single vpma promoter lies upstream of vpmaY and vpmaU genes thus leading to the stable ‘locked’ 
expression of VpmaY and VpmaU, respectively (Chopra-Dewasthaly et al., 2008). However, colony 
immunoblot analysis of some animal reisolates demonstrated Vpma phenotypes other than VpmaY 
and VpmaU. Two such clones, namely PLM16 and PLM18, when analysed via Western and colony 
immunoblotting clearly revealed that they had undergone Vpma switching to antigenically different 
Vpma proteins even in absence of the Xer1 protein. PLM16 shows reactivity exclusively with the α-W 
pAb, whereas PLM18 reacts only with the α-X pAb and both are negative for the expression of 
VpmaY and VpmaU, the original Vpma phenotype of PLMY and PLMU from which they originated 
(data not shown). In both clones, the absence of a functional xer1 gene was verified by Southern blot 
analysis (Fig. 7C, lanes 4 and 5) (Chopra-Dewasthaly et al., 2008). To further understand the 
molecular basis of Vpma switching in these xer1-disrupted clones, the vpma gene configuration of 
both clones was examined (Fig. 1 and Fig. 2).  
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PLM18 has undergone intergenic vpma recombination to generate hybrid vpma genes and 
altered Vpma phenotypes. Southern blot analysis using individual vpma-specific gene probes (Fig. 
7B, lanes 4), as well as sequencing of the PLM18 vpma locus demonstrated that its vpma configuration 
is similar to that of PLMY with the exception that two hybrid genes, vpmaYX’ and vpmaXY’ (Fig. 1B), 
are present instead of vpmaX and vpmaY of the type strain PG2. Located downstream to the single 
identified promoter, vpmaXY’ constitutes the expressed gene in PLM18 (Fig. 1B). Comparison of the 
coding sequence of the hybrid vpmaXY’ gene (Fig. 1C) with the original vpma sequences of the PG2 
clonal variant 55-5 and PLMY indicates that an intergenic recombination event has occurred at a 38-
bp sequence (Fig. 1C, bold letters) that is common to both vpmaX and vpmaY gene sequences. In the 
hybrid gene vpmaXY’, the sequence upstream of this 38-bp homologous region was found to be 100% 
identical with the vpmaY gene, whereas the downstream region showed complete identity with the 
sequence of vpmaX (Fig. 1C). Recombination at this 38-bp homologous sequence not only resulted in 
the generation of two hybrid genes, but also led to inversion of the promoter that resulted in the 
alteration of the observed Vpma phenotype depending on the specific Vpma antibody epitopes present 
in the downstream region (Fig. 1B). Since various conserved regions are repeated within different 
vpma genes, it would be not unlikely that generation of hybrid genes by homologous recombination 
represents a common mechanism for immune evasion. This view is supported by the fact that similar 
recombination events were also demonstrated in the vsp gene locus of the bovine pathogen M. bovis, 
the closest phylogenetic relative of M. agalactiae. Genetic analysis of clonal isolates derived from the 
M. bovis type strain PG45 revealed that intergenic recombination between two closely related 
members of the vsp gene family, vspA and vspO, led to the formation of the hybrid gene vspC 
(Lysnyansky et al., 2001). 
 
PLM16 has undergone complex vpma rearrangements leading to duplication and deletion of 
specific vpma genes. In contrast to PLM18, which contains hybrid vpma genes generated by 
intergenic recombination within homologous vpma regions, examination of the PLM16 vpma locus 
revealed a much more complex recombination scenario. Phenotypic expression of VpmaW in this 
clone correlates well with the sequencing analysis that reveals the presence of vpmaW gene located 
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downstream of the promoter (Fig. 2). Sequencing data also revealed the duplication of two vpma 
genes, namely vpmaX and vpmaW, as also supported by Southern blot analysis whereby two bands are 
observed with both vpmaW and vpmaX probes when the genomic DNA is digested with restriction 
enzymes that cut outside these genes, respectively (Fig. 7B, lane 5, vpmaW and vpmaX probes). 
Additionally, the sequence of PLM16 vpma locus showed that three genes, namely vpmaY, vpmaU and 
vpmaZ, are completely absent (Fig. 2). In accordance, no hybridization signal was observed during 
Southern blot analysis with probes specific for vpmaU, vpmaY and vpmaZ genes (Fig. 7B, lane 5, 
vpmaU, vpmaY and vpmaZ probes) clearly verifying the absence of these three genes. However, it is 
difficult to reconstruct the hierarchy of rearrangements that occurred in PLM16 that led to the final 
conformation seen in Fig. 2. The vpma configuration present in this clone is predicted to be a result of 
recombination events that occurred in PLMY. Although speculative, duplication of vpmaX and vpmaW 
could have placed the vpmaW gene downstream of the promoter, whose position is unaltered 
compared to PLMY, and simultaneously deleted the genomic fragment carrying vpmaU, vpmaY and 
vpmaZ (Fig. 2).  
In both the animal reisolates, significant vpma reshuffling has occurred under immune pressure in the 
native host, which clearly demonstrates the requirement of antigenic variation systems as a key feature 
for suvival during natural M. agalactiae infection. Despite Vpma phase variation by site-specific 
recombination, homologous recombination between conserved vpma sequences may alternatively 
represent an important immune evasion mechansim. 
 
In vitro immune pressure assay demonstrates bactericidal and growth inhibitory effect of 
Vpma-specific pAbs on M. agalactiae. To evaluate the role of Vpma-specific antibody response as a 
factor that triggers Vpma surface variation, as well as to investigate possible growth inhibitory effects 
of anti-Vpma pAbs, an in vitro immune pressure assay was established, whereby PG2 clonal variant 
55-5 (Glew et al., 2002) and xer1-disrupted mutant PLMY (Chopra-Dewasthaly et al., 2008), showing 
predominant and exclusive expression of VpmaY, respectively, were grown in presence of 
complement-inactivated VpmaY-specific α-Y pAb. The obvious difference between 55-5 and PLMY 
is that 55-5 is capable of switching to alternative Vpma phenotypes due to Xer1-mediated site-specific 
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vpma inversions (Glew et al., 2002; Chopra-Dewasthaly et al., 2008), whereas the xer1-deficient strain 
PLMY is blocked in the vpmaY expression phase and is unable to express any other Vpma protein 
(Chopra-Dewasthaly et al., 2008). Both strains were cultivated at 37°C in the presence of α-Y pAb 
over a period of 10 days. Cultures incubated in the presence of PBS served as negative controls. To 
monitor growth, aliquots of cultures were plated at the time of antibody addition and additionally after 
1, 2, 4, 7, 8 and 10 days of growth. CFU values were estimated by counting colonies under a 
stereomicroscope. Representative growth of 55-5 and PLMY in the presence and absence of the pAb is 
shown in Fig. 3. 
A significant decline in the PLMY population was observed after one day incubation in medium 
containing α-Y pAb, as concluded from the CFU values which dropped below the starting inoculum 
size of 106 cfu/ml (Fig. 3A). After this initial decline, PLMY recovers and shows some growth 
although this rate of growth is significantly lower than the control PLMY cultures grown in absence of 
α-Y pAb. This indicates that initial decline in CFU is a result of a strong immune pressure eliminating 
the majority of cells expressing VpmaY and eventual selection and growth of a small subpopulation of 
escape variants. We predicted that these cells are likely to stop VpmaY expression and then become 
capable of stable but reduced growth. In contrast, a slight initial delay in growth was observed for the 
wild-type strain 55-5 in α-Y pAb, which was then fully overcome at the end of two days (Fig. 3B). 
Since 55-5 is capable of Xer1-mediated Vpma phase variation, this initial delay may very well 
correlate with a time frame required for switching off the expression of the vpmaY gene and to switch 
on to new alternative Vpma phenotypes. These growth irregularities observed for both strains in the 
presence of VpmaY-specific antibodies suggest that Vpma phenotypic switching mechanisms serve 
significant roles in evading the host immune response during natural or experimental M. agalactiae 
infections. 
 
Clonal variant 55-5 escapes the growth inhibitory effect of α-Y pAb by switching to alternative 
non-VpmaY phenotypes via high-frequency Xer1-mediated vpma recombinations. To determine, 
whether the α-Y pAb could trigger Vpma switching in the wild-type strain 55-5, Vpma expression 
patterns of samples removed at the initial stage of immune pressure (2 days of incubation in α-Y pAb) 
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were analyzed by colony immunobloting. As shown in Fig. 4, growth of 55-5 in the presence of α-Y 
pAb induces switching from the predominant VpmaY phenotype to the expression of other five 
alternative Vpma proteins as indicated by the appearance of sectored colonies with α-Y pAb during 
colony immunostaining and the simultaneous appearance of sectored and positive colonies with other 
five Vpma-specific pAbs (Fig. 4). In contrast, control samples of 55-5 grown in PBS instead of α-Y 
pAb display a positive phenotype when immunostained with α-Y pAb and predominantly negative 
phenotypes with the remaining five pAb (Fig. 4). This clearly shows that the generation of Vpma 
antigenic variants in 55-5 is induced by α-Y pAb and that it is only because of this high-frequency 
Vpma switching to alternative non-VpmaY phenotypes that the clone 55-5 completely escapes the 
growth damaging effects of α-Y pAb as seen in Fig. 3. This could very well reflect the immune 
evasion capablity of wild-type M. agalactiae in the native immunocompetent host.  
 
Huge growth deficits due to α-Y pAb are partially overcome by PLMY by repressing the 
expression of VpmaY. Examination of PLMY growth rates revealed a significant reduction of the 
PLMY bacterial population in the presence of the α-Y pAb (Fig. 3A). Colony immunoblots of samples 
removed at 2 days of growth in α-Y pAb show that the majority of PLMY colonies now display a 
VpmaY negative phenotype indicating repression of the previous sole expression of VpmaY (Fig. 5A). 
In previous studies, analysis of the genomic organization of the vpma locus of PLMY revealed that 
vpmaY gene is the expressed gene located downstream of the unique promoter followed by the vpmaZ 
gene in the same transcriptional orientation (Chopra-Dewasthaly et al., 2008). As both genes are 
separated by a weak Rho-independent terminator structure, a weak read-through transcription of 
VpmaZ was detected by Western blot analysis (Chopra-Dewasthaly et al., 2008). However, in this 
study we used a different VpmaZ-specific α-Z pAb that revealed positive immunostaining of PLMY 
even during colony immunoblotting (data not shown) probably due its higher sensitivity compared to 
the α-Z pAb used in the previous study. Interestingly, although in presence of α-Y pAb PLMY 
switches off VpmaY expression, yet it still showed positive immunostaining with α-Z pAb (data not 
shown). This suggested that inhibition of VpmaY expression might be a result of a mutational event 
within vpmaY gene causing premature termination of VpmaY translation without affecting the read-
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through transcription of vpmaZ. And indeed, sequencing of such selected VpmaY negative clones 
revealed intragenic deletion within the vpmaY gene (Fig. 5B) corresponding to the loss of α-Y pAb 
recognition epitope. Originally, in PG2 and PLMY, the vpmaY gene consists of two large repeats of 
558 bp, out of which the second repeat (RY2’, Fig. 5B) is prematurely terminated due to the insertion 
of a stop codon (Glew et al, 2002; Chopra-Dewasthaly et al, 2008). However, in the sequenced 
VpmaY negative clones of PLMY, the 558 bp full length repeat (RY1, Fig. 5B) is found to be missing 
and the vpmaY gene constitutes only a single prematurely terminated version of the repeat, namely 
RY2’. This leads to the expression of a truncated VpmaY protein that lacks the epitope recognized by 
the α-Y pAb (Fig. 5B), which was originally encoded on the full length 558 bp repeat in PLMY. This 
very well correlates with the VpmaY negative phenotype observed during colony immunoblotting 
using α-Y pAb and clearly shows that intragenic vpmaY deletions constitute the molecular mechanism 
that led to VpmaY negative phenotype in PLMY when grown under α-Y pAb immune pressure. In 
contrast, PLMY samples incubated without the α-Y pAb show expression of both proteins, VpmaY 
(Fig. 5A) and VpmaZ and do not show any intragenic deletions in vpmaY sequence (data not shown). 
Furthermore, the α-Y pAb-induced VpmaY negative phenotype of PLMY clones was tested to be 
stable even after 20 passages in liquid media without any further selection in α-Y pAb (data not 
shown).  
 
PLMY can generate low frequency ‘escape’ variants in α-Y pAb. In order to assess if incubation in 
α-Y pAb can also trigger PLMY to express alternate Vpma phenotypes like 55-5, cultures exposed to 
the α-Y pAb selection pressure for 2 days were screened via colony immunoblotting to detect possible 
‘escape’ variants. For this, colony immunostaining was carried out with antibodies specifically 
recognizing VpmaU, VpmaV, VpmaW and VpmaX using agar plates seeded with a large number of 
colonies. Screening with α-Z pAb was omitted because of the likely read-through expression of 
VpmaZ in PLMY (Chopra-Dewasthaly et al., 2008). Indeed, a single fully stained colony designated 
X-EV (VpmaX expressing Escape Variant) could be identified on blots immunostained with VpmaX-
specific α-X pAb (Fig. 5C). Southern blot analysis verified disruption of the xer1 gene in the X-EV 
indicating that the Vpma-switchover has occurred in the absence of Xer1-mediated recombination 
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(Fig. 7C, lane 3). Colony blots of negative control cultures incubated with PBS instead of the α-Y 
pAb, did not show any such ‘switchovers’, neither with α-X pAb nor with any of the other three tested 
Vpma antisera (α-V pAb, α-W pAb and α-U pAb) (data not shown). To obtain a pure culture of the X-
EV, three successive rounds of filter cloning were carried out. Verification of the VpmaX phenotype 
was then accomplished by colony immunoblotting and Western blotting using all six α-Vpma pAbs, 
which clearly demonstrated that the X-EV shows reactivity exclusively with the α-X pAb, but not with 
any other α-Vpma pAb (Fig. 5D). The above data clearly reveal that M. agalactiae is capable of 
generating Vpma phase variants via alternative Xer1-independent mechanisms, especially under the 
selection pressure of specific Vpma antibodies. Although the in vitro rate of generation of such Vpma 
variants is significantly low especially when compared to the Xer1-mediated Vpma phase variation of 
55-5, yet it is possible that such ‘escape’ variants are generated at a higher frequency in the native 
immunocompetent host. 
 
Molecular characterization of the in vitro α-Y pAb induced X-EV escape variant of PLMY 
reveals a strong correlation with ‘escape’ variants generated in vivo during experimental PLM 
sheep infections. To further understand the molecular basis of the Xer1-independent escape 
mechanism which resulted in the in vitro alteration of the Vpma phenotype, the gene configuration of 
the vpma locus in the X-EV was examined. DNA sequencing revealed the presence of two hybrid 
vpma genes, designated as vpmaYX and vpmaXY (Fig. 6A), replacing the orginial vpmaX and vpmaY 
genes. The vpmaYX gene constitutes the expressed gene downstream of the vpma promoter, whereas 
the adjacent encoded vpmaXY is transcriptionally silent (Fig. 6A). Both hybrid genes share a common 
region of 42 bp, which is also present in the wild-type vpmaX and vpmaY genes, but the flanking 
regions are identical either with the vpmaX or vpmaY gene. Alignment of the expressed vpmaYX gene 
with vpmaY and vpmaX is shown in Fig. 6B. The sequence upstream of the common 42-bp region is 
identical with the sequence of the vpmaY gene, whereas the downstream adjacent region shows 100% 
identity with the vpmaX sequence (Fig. 6B). However, compared to the initial vpma locus of PLMY, 
the promoter orientation has also changed (Fig. 6A). Intergenic recombination could be further shown 
by Southern blot analysis. During intergenic recombination, a HindIII site present in the 5’ region of 
 75
the original vpmaY gene has switched to the 5’ region of the hybrid vpmaYX gene. HindIII and XbaI 
digestion of genomic DNA of the X-EV followed by hybridization with a vpmaX-specific probe 
detects a 0.5 kb HindIII fragment, which is not observed in PLMY, clearly verifying that intergenic 
recombination has occurred between vpmaX and vpmaY genes (Fig. 7B). This mechanism is similar to 
that described in escape variant PLM18, which was isolated from the animals, with the exception, that 
another conserved region common for both genes, vpmaY and vpmaX, was involved in recombination. 
Since similar recombination events also occurred in the animals, we propose that Vpma antibody 
response is likely to play a major role during immune evasion in the native host. The generation of 
hybrid genes by intergenic recombination between homologous vpma regions represents an alternative 
immune evasion mechanism that is predicted to act at frequencies much lower than Xer1-mediated 
recombination, which was demonstrated to occur at frequencies of 10-2-10-3 per cell per generation 
(Chopra-Dewasthaly et al., 2008). 
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FIG. 1. Generation of hybrid vpma genes as a result of immune evasion in the native host. (A) vpma 
configuration of PLMY and PLMU constituting the initial inoculum used for experimental infection of 
sheep: vpma genes are illustrated as large arrows in different colours, the unique promoter is shown as 
a bent arrow. PLMY shows exclusive expression of vpmaY, whereas PLMU exclusively expresses 
vpmaU found downstream of the unique promoter. (B) DNA sequence analysis of vpma configuration 
of PLM18 isolated from animals experimentally infected with an equimolar mixture of PLMY and 
PLMU: inversion of the promoter (crossed broken lines) and the generation of two hybrid vpma genes, 
vpmaYX’ and vpmaXY’ (indicated in blue/red colours), is illustrated. The vpmaXY’ gene constitutes the 
expressed gene located downstream of the vpma promoter, whereas the vpmaYX’ gene is 
transcriptionally silent. VpmaX phenotype of PLM18 can be explained by the fact that the coding 
sequence corresponding to the epitope recognized by α-X pAb is present at the 3’ end of the expressed 
vpmaXY’ gene (black bar). (C) Sequence alignment of the hybrid vpmaXY’ gene of PLM18 with the 
sequence of the original vpmaX and vpmaY genes: a 38-bp region common to both vpma genes (bold 
letters) is identified in the hybrid vpmaXY’ gene. The upstream region of the common 38-bp region in 
vpmaXY’ shows complete sequence identity with the vpmaY gene, whereas the downstream region is 
identical with the vpmaX gene, clearly indicating that the homologous 38-bp region was involved in an 
intergenic recombination event between vpmaX and vpmaY, which led to promoter inversion and 
generation of hybrid vpmaXY’ gene. 
 
FIG. 2. DNA sequencing of the vpma locus of PLM16 reveals gene duplications and deletions. The 
vpmaW gene is found downstream of the promoter (bent arrow) and correlates with the VpmaW 
phenotype of PLM16. DNA sequence analysis revealed the duplication of vpmaX and vpmaW, 
whereas vpmaY, vpmaU and vpmaZ are deleted. The coding sequence corresponding to the epitope 
recognized by α-W pAb is shown as a black bar below the vpmaW gene. Hypothetical gene 
duplication and deletion events, that could have occurred in PLMY and led to the vpma configuration 
of PLM16 are illustrated. 
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FIG. 3. Growth of 55-5 and PLMY in the presence of VpmaY-specific α-Y pAb. Representative 
growth of the xer1-mutant PLMY (A) and the wild-type strain 55-5 (B) in SP4 medium supplemented 
with α-Y pAb (triangles) and PBS (squares) is shown 
 
FIG. 4. High-frequency Vpma modulation in PG2 clonal variant 55-5 allows it to escape the damaging 
effects of VpmaY-specific α-Y pAb. Colony immunoblot analysis of PG2 clone 55-5 grown for 2 
days in absence (panel PBS) and in presence (panel α-Y pAb) of VpmaY-specific polyclonal 
antiserum. In PBS, clone 55-5 continues to predominantly express VpmaY and shows hardly any 
positive immunostained colonies with the other five monospecific Vpma pAbs, namely α-U, α-V, α-
W, α-X and α-Z, as designated below each column. In presence of α-Y pAb, 55-5 escapes its growth 
inhibitory effect (i) by repressing VpmaY expression (majority of colonies show negative or sectored 
colony immunoblot patterns with α-Y pAb) and (ii) by switching over to the other five Vpma 
phenotypes at a high frequency, as evident from the positive and sectored colony immunostaining 
patterns with α-U, α-V, α-W, α-X and α-Z pAbs. 
  
FIG. 5. VpmaY-specific antibody represses VpmaY expression and triggers low-frequency generation 
of alternate Vpma variants in the xer1-deficient PLMY clone. (A) α-Y pAb colony immunostaining 
patterns of PLMY incubated in the presence of α-Y pAb in comparison with control samples grown in 
PBS. Colonies corresponding to samples grown in α-Y pAb show a predominant negative phenotype 
(pink colour after staining with Ponceau S) indicating that VpmaY expression was repressed in the 
presence of the antibody, whereas colonies of control samples display a VpmaY positive phenotype 
(purple colour with CN staining). (B) Schematic representation of VpmaY (expressed in PLMY 
control samples incubated in PBS) including the full-length repeat RY1 and the premature terminated 
repeat RY2’ in comparison with the truncated version of VpmaY (expressed in the presence of α-Y 
pAb) where the RY1 repeat is missing; the leader sequence (L) of VpmaY is illustrated as a black box, 
the epitope recognized by α-Y pAb is shown as a black bar. (C) Detection of an ‘escape’ variant (X-
EV) under the growth inhibitory effect of α-Y pAb as observed during α-X pAb colony 
immunostaining. X-EV demonstrates positive staining (indicated by an arrow) whereas most other 
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colonies are negative and are visible as pink colonies only after Ponceau S staining. (D) Colony 
immunoblotting and Western blot analysis of the filter-cloned X-EV ‘escape’ variant using six 
monospecific Vpma pAbs, namely α-U, α-V, α-W, α-X and α-Z, as designated for each panel. X-EV 
displays positive staining only with the α-X pAb, but not with any of the remaining five α-Vpma 
pAbs. Whole cell extracts of PG2 cultures, expressing all six Vpma proteins, were used as positive 
controls in Western blot analysis. Strain PLMY, exclusively expressing VpmaY, and strain PLMU, 
exclusively expressing VpmaU, served as respective negative controls. 
 
FIG. 6. Genotypic analysis of the vpma locus of the α-Y pAb induced X-EV clone. (A) vpma gene 
configuration of the X-EV based on DNA sequencing is shown in comparison to that of PLMY 
constituting the initial vpma configuration before incubation in the α-Y pAb. vpma genes are 
illustrated as large arrows in different colours, the unique promoter is shown as a bent arrow. 
Incubation in α-Y pAb resulted in the generation of two hybrid vpma genes (vpmaXY and vpmaYX, 
indicated in blue/red colours) which are products of recombination within a 42-bp homologous region 
(vertical black lines) within the original vpmaX and vpmaY genes of PLMY. Recombination leads to 
inversion (crossed broken lines) of the promoter resulting in expression of the hybrid vpmaYX gene. 
The coding sequence of the epitope recognized by the α-VpmaX pAb (black bar) is located at the 3’ 
end of the vpmaYX gene. (B) Sequence alignment of the original vpmaX and vpmaY genes with the 
hybrid vpmaYX gene of the X-EV. Bold letters represent the 42-bp sequence common for both genes, 
vpmaX and vpmaY, which is also present in vpmaYX. The adjacent 5’ sequence shows sequence 
identity with vpmaY, whereas the downstream 3’ region is identical with vpmaX, indicating that the 
hybrid gene has been generated by homologous recombination within this homologous region. 
 
FIG. 7. (A) Restriction maps depicting the binding sites (black boxes) of vpma-specific gene probes 
within the vpma gene loci of PLMY, X-EV, PLM18 and PLM16: H, HindIII; P, PstI; X, XbaI. (B) 
Southern blot analysis using vpma-specific probes: DIG-labeled DNA size marker (lane 1), PLMY 
carrying all six vpma genes was used as a positive control (lane 2), X-EV (lane 3), PLM18 (lane 4) 
and PLM16 (lane 5); HindIII/XbaI digested genomic DNA probed with vpmaU-specific probe detects 
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a 2.8 kb HindIII/XbaI fragment corresponding to the vpmaU gene in PLMY, X-EV and PLM18, which 
is absent in PLM16; HindIII/XbaI digested DNA probed with vpmaV-specific probe detects a 2.1 kb 
HindIII/XbaI fragment corresponding to the vpmaV gene present in all samples; HindIII digested DNA 
probed with vpmaW-specific probe detects a 2.8 kb HindIII fragment corresponding to the vpmaW 
gene in all samples, whereas an additional 2.6 kb HindIII fragment indicates duplication of vpmaW in 
PLM16; HindIII/XbaI digested DNA probed with vpmaX-specific probe verifies intergenic 
recombination between vpmaX and vpmaY in the X-EV: the HindIII site, originally present in the 5’ 
region of vpmaY switched to the 5’ end of the hybrid vpmaYX gene during recombination, the 
corresponing 0.5 kb HindIII fragment is detected after hybridization with a vpmaX-specific probe, a 
1.7 kb HindIII fragment corresponds to vpmaX gene in PLMY and to the vpmaX-derived sequence of 
the hybrid vpmaYX’ gene in PLM18, the presence of two HindIII/XbaI-fragments (0.8 kb and 1.9 kb) 
indicates duplication of vpmaX in PLM16; PstI digested DNA probed with a vpmaY-specific probe 
detects a 0.6 kb PstI fragment corresponding to the vpmaY gene in PLMY. In the vpmaY-derived 
sequence of the hybrid vpmaXY (X-EV) and vpmaYX’ (PLM18) genes an additional 1.7 kb-PstI 
fragment is observed corresponding to an adjacent untranscribed repeat of vpmaY and both these 
fragments are absent in PLM16; HindIII/XbaI digested DNA with vpmaZ-specific probe detects a 2.8 
kb HindIII/XbaI fragment corresponding to the vpmaZ gene in PLMY, X-EV and PLM18, which is 
absent in PLM16. (C) Verification of xer1-disruption in X-EV (lane 3), PLM18 (lane 4), PLM16 (lane 
5) using ClaI-digested genomic DNA and a xer1-specific probe was accomplished as described by 
Chopra-Dewasthaly et al. (2008); genomic DNA of PG2 (lane 1) and PLMY (lane 2) were used as 
negative and positive controls, DIG-labeled DNA size marker (lane 6). 
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Sequence (5’ to 3’)  Reference 
1618P1 GCCCCATAATTAGAGCCC This study 
C1F CCGGAATTCGTTGAGGAAGCAATTAAAACAGC Chopra-Dewasthaly et al, 2008
C1R GCTCTAGATTATCCAGATGTTTCAACTTC Chopra-Dewasthaly et al, 2008
P2BPLMY GGTGGTAGCACATCAACTG This study 
P2PLMU TTTGAAGATGTGTTGGATG This study 
P6PLMU CTCCAGCAGAAGGCAGTC This study 
P6PLMY AGCGTTTGCATTGGCTAC This study 
P7PLMU GTTACATTTACTGGAACTG This study 
P7PLMY TTTTGTTGCCTAGTTTCTG This study 
P8PLMU TAACGTCAGCAATGTCTG This study 
P8PLMY TTATAGCCATTAAAGAAAGG This study 
P9PLMU AGGCCTCATAATTATGAAG This study 
P9PLMY AGTTTAGATTGACCTTTGG This study 
Prlocol1 CAAGTTATCAAGTTGCATGTAG This study 
PrSq1 AGCAAGGCAAAATTCAGAATATCTC This study 
PrSq2 AACTAAAACATTCTGTAATCTTAG This study 
TetMEnd ACGCATAGTAGACCACCTC This study 
U2F CGCGGATCCGATAAAGAAGATAAGACAGGTG Chopra-Dewasthaly et al, 2008
Urev1 TCAACCTTAGATAAATCACCTAAC This study 
Urevvw4 GTTCTATCATGTCACTAGTTTG This study 
Vendrv TAAATTTGAAGTATAAGTGA This study 
WDIGfw CAACAATTAGGTGAAATCAAGAAG This study 
WDIGrv AGAAGCATTTAAAGTGAATGAAACC This study 
Wstfw TGATTTCTTTTCGTTTGTTG This study 
X1F CGCGGATCCAAAGTAATGAAGGTCAATTACC Chopra-Dewasthaly et al, 2008
X1R AAACTGCAGGCTTAAGGATTTTTTAAAATGATG Chopra-Dewasthaly et al, 2008
Y3F CCGAATTCAATGCAAACGCTGCAGAAAATG Chopra-Dewasthaly et al, 2008
Y3R GCTCTAGATTAAGTAAATGTAACTGTAACTTCACC Chopra-Dewasthaly et al, 2008
Yrevpr5 ATTAGTAGAAGATTGTAGCG This study 
Yrevv8 TTGTGCTTGCCTGTTACC This study 
Z1F CGCGGATCCCAAACAGATTCAACTCCGTCAAC Chopra-Dewasthaly et al, 2008
Z2R AAACTGCAGTTATTCGTATTTAGGTAATAGTCTTC Chopra-Dewasthaly et al, 2008




















6.1 Solutions and Media 
6.1.1 Media, media additives and antibiotics  
SP4 Broth    0.35% mycoplasma broth base (Oxoid) 
1% tryptone (Oxoid)  
0.53% peptone (Merck) 
pH 7.8 with NaOH (Sigma) 
autoclaved at 120°C for 20 min 
 
17 ml/100 ml heat inactivated fetal calf serum (Gibco) 
5 ml/100 ml CMRL (Invitrogen) 
5 ml/100 ml 4% aqueous yeastolate solution (Difco) 
2.5 ml/100 ml 15% filter sterile yeast extract (Merck) solution  
1 ml/100 ml 50% filter sterile glucose (Roth) solution  
1 ml/100 ml 0.5% filter sterile phenol red solution (ICN 
Biomedicals) 
2 ml/100 ml 25% filter sterile sodium pyruvate (Sigma) 
solution  
 
SP4 Agar Plates   SP4 broth with 
1% noble agar (Difco) before autoclaving 
ddH2O instead of phenol red and sodium pyruvate solutions 
 
LB Broth    5% yeast extract (Merck) 
10% NaCl  (Roth) 
10% tryptone (Oxoid) 
 
LB Agar Plates    LB broth with 
1.5% agar (Oxoid) 
 
Ampicillin Stock (Roth)  100 mg/ml in ddH2O 
 
Tetratcycline Stock (Sigma)  10 mg/ml in ddH2O 
 
Gentamicin Stock (Roth)  10 mg/ml in ddH2O 
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Glucose Stock (Roth)   50% in ddH2O, filter sterile 
      
Arabinose Stock (Roth)   10% in ddH2O, filter sterile 
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6.1.2 Southern blot analysis 
Depurination Solution   250 mM NaCl (Roth)  
 
Denaturation Solution   500 mM NaOH (Roth) 
1.5 M NaCl (Roth) 
 
Neutralization Solution   500 mM Tris (Roth) 
3 M NaCl (Roth) 
pH 7.5 adjusted with HCl (Roth) 
 
20 x Sodium Chloride /   3 M NaCl (Roth)    
Sodium Citrate Buffer (SSC)  300 mM sodium citrate (Roth) 
 
Maleic Acid Buffer   100 mM maleic acid (Roth) 
150 mM NaCl (Roth) 
pH 7.5 adjusted with NaOH (Roth) 
 
Washing Solution   maleic acid buffer 
     0.3% Tween 20 (Roth) 
      
Blocking Solution   maleic acid buffer 
     1% blocking reagent (Roche) 
 
Detection Buffer   100 mM Tris (Roth) 
100 mM NaCl (Roth) 
pH 9.5 adjusted with NaOH (Roth) 
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6.1.3 Agarose gel electrophoresis 
6 x DNA Loading Buffer  40% glycerol (Roth) 
0.1% bromophenol blue (Sigma) 
 
50 x TAE    2 M Tris (Roth) 
     1 M acetic acid (Roth) 
     500 mM EDTA (Merck) 
 
Agarose Gel    0.8 - 1% agarose (Roth) boiled in 1 x TAE 
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6.1.4 DNA isolation 
Washing Solution   250 mM NaCl (Roth) 
     100 mM EDTA (Merck) 
 
Suspension Solution   50 mM Tris pH 8.0 (Roth) 
10 mM EDTA (Merck) 
 
Phenol / Chloroform / 
Isoamyl Alcohol Solution 
(25:24:1)    (Sigma) 
 
TE Buffer    10 mM Tris pH 8.0 (Roth) 
1 mM EDTA (Merck) 
 
RNase Stock (Roth)   10 mg/ml in ddH2O 
 
Proteinase K Stock (Roth)  10 mg/ml in 10 mM Tris pH 8.0 (Roth) 
 
Potassium Acetate   5 M potassium acetate (Roth) in ddH2O 
 
Sodium Acetate   3 M sodium acetate (Roth) 
     pH 5.2 adjusted with HCl (Roth) 
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6.1.5 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
APS Solution    10% ammonium peroxide sulfate (Roth) in ddH2O 
 
40% Acrylamid Solution  (Roth) 
 
Urea Stock    30% urea (Roth) in ddH2O 
 
SDS Stock    10% SDS (Roth) in ddH2O 
 
TEMED Solution   (Roth) 
 
Resolving Gel Buffer   1.5 M Tris (Roth) 
pH 8.8 adjusted with HCl (Roth) 
 
Stacking Gel Buffer   1 M Tris (Roth) 
pH 6.8 adjusted with HCl (Roth) 
 
5 x Loading Buffer   250 mM Tris-HCl pH 6.8 (Roth) 
50% glycerol (Roth) 
10% SDS (Roth) 
7.5% DTT (Roth) 
0.1% bromophenol blue (Sigma) 
 
10 x Laemmli Electrode Buffer  250 mM Tris (Roth) 
(LEB)     1.9 M glycine (Roth) 
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6.1.6 Western blot and colony blot analysis 
10 x Tris Buffered Saline   1.5 M NaCl (Roth) 
(TBS)     100 mM Tris (Roth) 
pH 7.4 adjusted with HCl (Roth) 
 
TBS Tween    1 x TBS 
     0.05% Tween 20 (Roth) 
 
Ponceau Stain    0.25% Ponceau S (Roth) 
5% acetic acid (Roth) 
 
Blocking Solution    3% milkpowder (Bio-Rad) in 1x TBS 
 
CN Stock 0.3% 1-chloro-4-naphthol (Bio-Rad) in 100% methanol (Roth) 
 
CN Working Solution   2 ml CN stock 
10 ml 10 x TBS 
10 µl H2O2 
 
Blotting Buffer    1 x LEB 
20% methanol (Roth) 
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6.2 Plasmid constructs 
6.2.1 Symbols and abbreviations 
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6.2.2 Construction of plasmid pBADRS21x2 
 
Step 1: RS21 was cloned into HindIII and XbaI sites of pBAD24 (Guzman et al., 1995) leading to 
plasmid pBADRS21 
Step 2: RS21 was cloned into NarI and NsiI sites of pBADRS21 leading to plasmid pBADRS21x2 
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6.2.3 Construction of plasmid pBADXerRS21 
 
xer1 was cloned into NcoI and SmaI sites of pBADRS21 leading to plasmid pBADXerRS21 
 99
6.2.4  Construction of plasmid pBADXerRS21x2 
 
xer1 was cloned into NcoI and SmaI sites of pBADRS21x2 leading to plasmid pBADXerRS21x2 
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6.2.5 Construction of plasmid pBADXerIR200Y 
 
Step 1: RS200Y was cloned into HindIII and XbaI sites of pBAD24 leading to plasmid pBADRS 
Step 2: RS200Y was cloned into NarI/ClaI and NsiI sites of pBADRS leading to plasmid pBADRSIR 




6.2.6 Construction of plasmid pBADXerDR200Y 
 
Step 1: RS200Y was cloned into HindIII and XbaI sites of pBAD24 leading to plasmid pBADRS 
Step 2: RS200Y was cloned into NarI/ClaI and NsiI sites of pBADRS leading to plasmid pBADRSDR 
Step 3: xer1 was cloned into NcoI and SmaI sites of pBADRS21x2 leading to plasmid 
pBADXerDR200Y 
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6.2.7 Construction of plasmid pBADXerIR21Y 
 
RS21Y was cloned into HindIII and XbaI digested pBADXerIR200Y to replace RS200Y leading to 
plasmid pBADXerIR21Y 
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6.2.8 Construction of plasmid pBADXerIR31Y3’ 
 
RS31Y3’ was cloned into HindIII and XbaI digested pBADXerIR200Y to replace RS200Y leading to 
plasmid pBADXerIR31Y3’ 
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6.2.9 Construction of plasmid pBADXerIR56Y3’ 
 
RS56Y3’ was cloned into HindIII and XbaI digested pBADXerIR200Y to replace RS200Y leading to 
plasmid pBADXerIR56Y3’ 
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6.2.10 Construction of plasmid pBADXerIR111Y 
 
RS111Y was cloned into HindIII and XbaI digested pBADXerIR200Y to replace RS200Y leading to 
plasmid pBADXerIR111Y 
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6.2.11 Construction of plasmid pBADXerIR57Y5’ 
 




6.2.12 Construction of plasmid pBADXerIR200Y/184U 
 
RS184U was cloned into HindIII and XbaI digested pBADXerIR200Y to replace RS200Y leading to 
plasmid pBADXerIR200Y/184U 
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6.2.13 Construction of plasmid pBADXerIR200Y/56X5’ 
 
RS56X5’ was cloned into HindIII and XbaI digested pBADXerIR200Y to replace RS200Y leading to 
plasmid pBADXerIR200Y/56X5’ 
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6.2.14 Construction of plasmid pBADXerIR53U5’/57Y5’ 
 
RS53U5’ was cloned into MscI and BstAPI digested pBADXerIR57Y5’ to replace RS200Y leading to 
plasmid pBADXerIR53U5’/57Y5’ 
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6.2.15 Construction of plasmid pIL 
 
lacZ was cloned into BamHI and SmaI sites of pISM2062 (Knudtson and Minion, 1993) leading to 
plasmid pIL 
 111
6.2.16 Construction of plasmid pILDR 
 
Step 1: RS184U was cloned into BamHI and NcoI sites of pIL leading to plasmid pILRSU 
Step 2: RS200Y was cloned into BglII site of pILRSU leading to plasmid pILDR 
 112




Ich möchte mich ganz herzlich bedanken... 
 
bei meiner Dissertationsbetreuerin Prof. Dr. Dr. habil. Renate Rosengarten, die mir die 
Möglichkeit gab, meine Dissertationsarbeit am Institut für Bakteriologie, Mykologie und 
Hygiene der Veterinärmedizinischen Universität Wien durchzuführen. Zusätzlich 
möchte ich mich bedanken, dass ich bei so vielen nationalen und internationalen 
Kongressen aktiv teilnehmen durfte, die für mich eine sehr wertvolle Erfahrung waren. 
 
bei der Arbeitsgruppenleiterin innerhalb der Mykoplasmen-Forschungsgruppe Dr. Rohini 
Chopra-Dewasthaly, die mich über fast sechs Jahre im Labor begleitet und betreut hat. 
Aufgrund ihrer langjährigen Erfahrungen durfte ich viel von ihr lernen. Vielen Dank für 
unser freundschaftliches Arbeitsverhältnis und für die nette Unterstützung bei der 
Labortätigkeit und beim Erstellen meiner Dissertation und meines Manuskriptes. 
 
bei Prof. Dr. Angela Witte für ihre nette administrative Unterstützung in 
Studienangelegenheiten und für ihre wertvollen fachlichen Anregungen beim Erstellen 
meines Manuskriptes. 
 
bei Dr. Micheal Szostak für seine hilfreiche Diskussion in fachlichen Fragen und für das 
Lösen von Computerproblemen 
 
bei den technischen Assistenten Mag. Martina Zimmermann und Karin Siebert-Gulle, 
ohne die ich im Labor sehr oft verloren gewesen wäre. 
 
bei meinen Kollegen Dr. Gunther Vogl, Dr. Ivana Indikova, Mag. Martin Vronka, Mag. 
Shivanand Hegde, Dr. Ursula Fürnkranz, Mag. Isolde Nieszner und Dr. Carl-Ulrich 
Zimmerman, die mir bei der täglichen Labortätigkeit eine große Hilfe waren. 
 
bei Isabell Polonyi, Helga Brödl und Christine Schramm für ihre nette administrative 
Unterstützung. 
 
bei meiner Freundin Cathrien Egger für ihre seelische Unterstützung in Zeiten, wo es 
nicht so gut lief. 
 
bei meinen Eltern Erhard and Erika Czurda für die langjährige finanzielle Unterstützung 
während meines Studiums. 
 114
 
Curriculum Vitae  
Personal Data 
 
Date of birth: May 10, 1978  





2000-2004 Study of Microbiology and Genetics with the main topic in Molecular Microbiology at  
  the University of Vienna 
2004-2006 Diploma thesis (‘Molecular Analysis of Antigenic Variation in Mycoplasma 
agalactiae’) at the Institute of Bacteriology, Mycology and Hygiene, University of 
Veterinary Medicine Vienna, Mycoplasma research group 
2006  Master of Science (with honours) 
2006-2010 Dissertation at the Institute of Bacteriology, Mycology and Hygiene, University of 
Veterinary Medicine Vienna, Mycoplasma research group 
Publications 
Research paper 
Stefan Czurda, Wolfgang Jechlinger, Renate Rosengarten, and Rohini Chopra-Dewasthaly. Xer1-
Mediated Site-Specific DNA Inversions and Excisions in Mycoplasma agalactiae  
J. Bacteriol. published ahead of print on 18 June 2010, doi:10.1128/JB.01537-09 
 
Posters 
Stefan Czurda*, Rohini Chopra-Dewasthaly, Christine Citti, Renate Rosengarten, Wolfgang 
Jechlinger (2006). Function of the Xer1 recombinase of Mycoplasma agalactiae in Escherichia coli. 
 115
16th International Congress of the International Organization for Mycoplasmology (IOM), Cambridge, 
UK, July 9th-14th 2006 
 
Stefan Czurda*, Rohini Chopra-Dewasthaly, Christine Citti, Renate Rosengarten, Wolfgang 
Jechlinger (2008). The rate of Vpma switching in Mycoplasma agalactiae is influenced by sequences 
flanking the specific Xer1 recombination-site. 17th International Congress of the International 
Organization for Mycoplasmology (IOM), Tianjin, P.R. China, July 6th-11th 2008 
 
Rohini Chopra-Dewasthaly*, Stefan Czurda, Martina Zimmermann, Joachim Spergser, Renate 
Rosengarten (2010). The many facets of the Vpma antigenic variation system of Mycoplasma 
agalactiae. 110 th General meeting of ASM, San Diego, CA, USA, May 23th-27th 2010 
 
Stefan Czurda, Shivanand Hegde, Martina Zimmermann, Renate Rosengarten, and Rohini Chopra-
Dewasthaly* (2010). Xer1-independent mechanisms of Vpma phase variation are triggered by the host 
immune response. 17th International Congress of the International Organization for Mycoplasmology, 
Chianciano Terme, Siena, Italy, July 11th-16th 2010 
 
Oral presentations 
Stefan Czurda*, Rohini Chopra-Dewasthaly, Christine Citti, Renate Rosengarten, Wolfgang 
Jechlinger (2007). Die Xer1 Rekombinase von Mycoplasma agalactiae: Inversionen und Exzisionen. 
6. deutschsprachiges Mykoplasmen-Symposium, Fürth, Deutschland, 28.Juni - 1.Juli 2007  
 
Stefan Czurda*, Wolfgang Jechlinger, Christine Citti, Renate Rosengarten, Rohini Chopra-
Dewasthaly (2009). Identifikation von ortsspezifischen DNA-Exzisionen in Mycoplasma agalactiae 
mithilfe des lacZ-Reportergens. 7. deutschsprachiges Mykoplasmen-Symposium, Morschach, 
Schweiz, 25. - 27.Juni 2009 
 
 116
Stefan Czurda, Wolfgang Jechlinger, Christine Citti, Renate Rosengarten, and Rohini Chopra-
Dewasthaly* (2009). Identification of Xer1-mediated excisions in Mycoplasma agalactiae by a lacZ-
based reporter system. Mycoplasmology - A Review of developments over the last decade, Gran 
Canaria, Spain, June 10th-12th 2009 
 
Stefan Czurda*, Wolfgang Jechlinger, Renate Rosengarten, Rohini Chopra-Dewasthaly (2010). 
Xer1-mediated site-specific DNA inversions and excisions in Mycoplasma agalactiae. 32. 
Jahrestagung der Österreichischen Gesellschaft für Hygiene, Mikrobiologie und Präventivmedizin 
(ÖGHMP), Wien, Österreich, 17. - 20.Mai 2010 
 
Rohini Chopra-Dewasthaly*, Stefan Czurda, Shivanand Hegde, Martina Zimmermann, Renate 
Rosengarten (2010). The many facets of Vpma surface antigenic variation in Mycoplasma agalactiae. 
32. Jahrestagung der Österreichischen Gesellschaft für Hygiene, Mikrobiologie und Präventivmedizin 
(ÖGHMP), Wien, Österreich, 17. - 20.Mai 2010 
 
*presenting author 
 
 
 
 
 
